Triamterene

Authoritative Clinical Reference

DRUG NAME: Triamterene

ℹ️ INN (International Nonproprietary Name): Triamterene. No name discrepancy between INN and Indian market usage. The USAN is identical.

Chemical class: Pteridine derivative. Triamterene is structurally unrelated to amiloride (a pyrazine derivative), the other ENaC-inhibiting potassium-sparing diuretic — though both share the same target.

Therapeutic Class:

Diuretic

Subclass:

Potassium-sparing diuretic — Epithelial sodium channel (ENaC) inhibitor

Triamterene directly blocks the luminal ENaC in the principal cells of the late distal convoluted tubule and cortical collecting duct, reducing sodium reabsorption and, secondarily, diminishing the lumen-negative electrical gradient that drives potassium and hydrogen ion secretion. Its action is independent of aldosterone — distinguishing it mechanistically from the mineralocorticoid receptor antagonists (spironolactone, eplerenone).

Schedule (India):

Schedule H

All triamterene-containing formulations — single-ingredient and FDCs — require a valid prescription. No formulation carries OTC status. Not listed under Schedule H1 or Schedule X. No NDPS Act implications.

Route(s)

Oral (capsules, tablets — single-ingredient and FDC formulations)

No parenteral, topical, or other non-oral formulations of triamterene are manufactured or marketed.

Biosimilar Status:

Not a biologic — biosimilar classification not applicable. Triamterene is a small-molecule chemical drug synthesised by conventional chemical methods.

Formulations Available in India

ℹ️ Limited Indian regulatory documentation available for a standalone single-ingredient triamterene CDSCO monograph. Pharmacokinetic and dosing data are derived from Goodman & Gilman, standard clinical pharmacology references, and available FDC product information in India.

Single-Ingredient Formulations:

Dosage Form	Strengths
Capsules / Tablets	50 mg, 100 mg

⚠️ Single-ingredient triamterene has very limited retail availability in the Indian market. It is predominantly prescribed and dispensed as fixed-dose combinations. Prescribers seeking single-ingredient triamterene may need to source it through hospital pharmacies, select online pharmacy platforms, or compounding. Confirm current availability before prescribing.

Fixed-Dose Combinations (FDCs) Available in India:

FDC Partner	Strengths Available	Notes
Benzthiazide	Triamterene 50 mg + Benzthiazide 25 mg	Historically one of the most widely prescribed triamterene-containing products in India, especially in primary care. Benzthiazide is a lower-potency thiazide-type diuretic compared to hydrochlorothiazide.
Hydrochlorothiazide (HCTZ)	Triamterene 50 mg + HCTZ 25 mg	Available from select manufacturers; availability may be limited to metro/urban centres

ℹ️ The Triamterene + Benzthiazide FDC has a long-established history of use in Indian hypertension management. The rationale for the combination is pharmacologically sound: the thiazide component provides the primary natriuretic and antihypertensive effect, while triamterene counteracts thiazide-induced potassium wasting. This is a rational FDC.

⛔ No triamterene-containing formulations or FDCs have been banned or withdrawn by CDSCO based on available information as of the date of this monograph.

💡 FDC vs. Separate Components: In Indian practice, the FDC is overwhelmingly preferred for convenience and adherence. When single-ingredient triamterene is needed (e.g., to combine with a different thiazide or loop diuretic at independent dose titration), the prescriber should verify sourcing before writing the prescription.

PHARMACOKINETICS

Main Pharmacokinetic Parameters

Parameter	Details
Bioavailability (oral)	~30–70% (highly variable between individuals and occasions). Significantly increased when taken with food — both rate and extent of absorption are enhanced.
Tmax	Parent drug: 1.5–3 hours. Active metabolite (hydroxytriamterene sulfate): 2–4 hours.
Protein binding	~55–67% (plasma protein binding, predominantly to albumin)
Volume of distribution (Vd)	Data limited; estimated approximately 1.5 L/kg from limited pharmacokinetic studies, suggesting moderate tissue distribution
Metabolism	Extensive hepatic metabolism via two sequential steps: Phase I — hydroxylation to 4’-hydroxytriamterene; Phase II — sulfate conjugation by sulfotransferases to p-hydroxytriamterene sulfate (also designated 4’-hydroxytriamterene sulfate), the major circulating and pharmacologically active metabolite. No significant CYP enzyme involvement documented — the hydroxylation is not mediated by major CYP isoenzymes. Triamterene does not significantly inhibit or induce CYP1A2, CYP2C9, CYP2C19, CYP2D6, or CYP3A4.
Active metabolite	p-Hydroxytriamterene sulfate — retains clinically significant potassium-sparing diuretic activity; achieves higher and more sustained tubular concentrations than the parent drug; is the predominant circulating form and the primary contributor to the clinical duration of action.
Half-life (t½)	Parent drug: ~1.5–2 hours (rapid hepatic extraction). Active metabolite: ~3–5 hours. Both are prolonged in renal impairment (metabolite accumulation) and hepatic impairment (reduced parent drug clearance).
Excretion	Primarily renal (~50–70% of the dose excreted in urine, mostly as conjugated metabolites; only a small fraction as unchanged parent drug). ~20% via biliary/fecal route. ⚠️ Parent drug and metabolites are relatively insoluble in acidic urine — this underlies the risk of triamterene crystalluria and nephrolithiasis.
Dialysability	Poorly dialyzable. Not effectively removed by haemodialysis (due to protein binding and tissue distribution). Peritoneal dialysis: not significantly removed. CRRT: Data limited, but unlikely to be significantly cleared.
Food effect	Bioavailability significantly increased with food (both rate and extent of absorption enhanced). Recommend administration after meals. Fasting reduces absorption unpredictably.
Onset of action	2–4 hours (onset of diuretic and potassium-sparing effect)
Duration of action	7–9 hours for the primary diuretic effect; may extend to ~12 hours due to the sustained activity of the active metabolite. This is shorter than spironolactone’s duration but longer than amiloride’s in some dosing regimens.

Additional Pharmacological Property (Clinically Relevant)

Triamterene possesses weak dihydrofolate reductase (DHFR) inhibitory activity — a pharmacodynamic property, not a pharmacokinetic interaction. This can contribute to megaloblastic anaemia with prolonged use, particularly in patients with pre-existing folate deficiency, alcoholism, or concurrent anti-folate drug therapy (e.g., methotrexate, trimethoprim, pyrimethamine). This is addressed further under Adverse Effects and Drug Interactions.

Drug Transporter Interactions

Transporter	Role for Triamterene	Clinical Relevance
OAT1 (SLC22A6)	The active metabolite (hydroxytriamterene sulfate) is a substrate for OAT1	Mediates active tubular secretion of the metabolite. Competition at OAT1 by other organic anion substrates (e.g., indomethacin, probenecid) may reduce metabolite clearance and alter drug levels.
OAT3 (SLC22A8)	The active metabolite is a substrate for OAT3	Similar to OAT1 — contributes to renal secretory clearance of the metabolite.
OCT2 (SLC22A2)	Triamterene (parent) may interact with OCT2 at the renal tubule	Clinical significance not well established; possible contributor to renal handling of parent drug.
P-glycoprotein (P-gp)	No significant substrate, inhibitor, or inducer activity documented	Not clinically relevant for this drug.
BCRP, OATP1B1/1B3, MATE1/2, PEPT1/2	No clinically documented substrate, inhibitor, or inducer activity	Not relevant for this drug.

Non-Linear Pharmacokinetics

No clinically significant non-linear pharmacokinetics, autoinduction, or saturation kinetics documented within the therapeutic dose range (50–300 mg/day). The high inter-individual variability in bioavailability is attributable to variable first-pass extraction rather than dose-dependent non-linearity.

PK–PD Relationship

Triamterene exerts its pharmacological effect by reaching the luminal (apical) surface of ENaC in the principal cells of the collecting duct. The drug must be present in the tubular fluid to block the channel — therefore, tubular drug concentration (not systemic plasma concentration) is the primary determinant of efficacy. The active metabolite (p-hydroxytriamterene sulfate), which is efficiently secreted into the tubular lumen via OAT transporters, achieves higher and more sustained tubular concentrations than the parent drug and is responsible for a substantial proportion of the overall potassium-sparing diuretic effect.

ℹ️ Clinical Implication: In renal impairment, the drug’s ability to reach the tubular lumen is reduced (less filtered drug, less OAT-mediated secretion) → diminished diuretic efficacy but paradoxically enhanced systemic accumulation → net effect is reduced therapeutic benefit with increased risk of hyperkalemia. This is the fundamental pharmacokinetic rationale for avoiding triamterene in advanced renal impairment.

Population PK Notes

Population	PK Alteration	Clinical Implication
Elderly (≥60 years)	Reduced renal clearance of active metabolite (age-related GFR decline); reduced hepatic first-pass metabolism → increased parent drug bioavailability. Net: higher overall drug exposure and prolonged effect.	Dose reduction recommended. Risk of hyperkalemia significantly increased, especially when combined with ACE inhibitors/ARBs or potassium supplements — a common scenario in elderly Indian patients with hypertension and heart failure.
Renal impairment	Significant accumulation of parent drug and active metabolite. Potassium-sparing effect enhanced disproportionately to natriuretic effect.	Contraindicated in severe renal impairment (eGFR <30 mL/min). Use with extreme caution in moderate impairment (eGFR 30–60 mL/min) with frequent potassium monitoring. See Renal Adjustment (Part 3).
Hepatic impairment	Reduced first-pass hepatic metabolism → increased oral bioavailability of parent drug. Metabolite formation may be delayed. In cirrhosis with ascites, altered drug distribution may also occur.	Use with caution in moderate impairment (Child-Pugh B). Avoid in severe impairment (Child-Pugh C). See Hepatic Adjustment (Part 3).
Paediatric	Limited PK data. Renal and hepatic maturation in younger children affects clearance. Neonatal renal immaturity significantly reduces drug clearance.	Weight-based dosing extrapolated from limited data. See Paediatric Dosing (Part 3).
Pregnancy	Limited PK data. Triamterene crosses the placenta. Theoretical risk of fetal electrolyte disturbances.	Use generally avoided during pregnancy. See Pregnancy (Part 4).
Obesity	No clinically significant population PK differences documented.	Standard dosing applicable.
Critical illness / ICU	Data limited. Altered Vd (fluid overload states), unpredictable renal clearance (AKI common), and variable hepatic function may affect drug disposition.	Oral absorption may be impaired in critically ill patients. Monitor potassium closely if used. Limited role in ICU — IV diuretics (furosemide) preferred for acute fluid management.

ADULT INDICATIONS + DOSING

⚠️ This section is for qualified prescribers only. Not for patient self-treatment.

Combination Therapy Positioning (Antihypertensive Class-Specific)

ℹ️ Triamterene is NOT intended for use as a sole antihypertensive agent. Its natriuretic potency is weak (~2–5% of the filtered sodium load compared with ~5–8% for thiazides and ~20–25% for loop diuretics). Its primary clinical value lies in counteracting potassium and magnesium losses induced by more potent diuretics (thiazides and loop diuretics) when these are used for hypertension or edema management.

Preferred combination partners:

✔ Thiazide / thiazide-type diuretics (benzthiazide, hydrochlorothiazide, chlorthalidone, indapamide) — most common and pharmacologically rational pairing
✔ Loop diuretics (furosemide, torsemide) — in edema management when loop diuretic–induced hypokalemia is problematic

Combinations to AVOID:

⛔ ACE inhibitors or ARBs + triamterene — significant hyperkalemia risk; if this triple combination is unavoidable, mandate frequent potassium monitoring (see Major Drug Interactions, Part 4)
⛔ Spironolactone or eplerenone + triamterene — additive potassium-sparing effect with unacceptable hyperkalemia risk; no clinical rationale for combining two potassium-sparing diuretics
⛔ Amiloride + triamterene — same mechanism class; no therapeutic benefit, doubled toxicity risk
⛔ Potassium supplements (KCl) + triamterene — severe hyperkalemia risk unless under close specialist monitoring with documented hypokalemia

Where triamterene fits in the step-up algorithm for hypertension (Indian context):

Triamterene (usually as an FDC with a thiazide) is not a first-step antihypertensive in current Indian or international guidelines. The Indian Guidelines on Hypertension (IGH-IV) and API recommendations position the following as first-line:

ACE inhibitor or ARB
Calcium channel blocker (amlodipine)
Thiazide/thiazide-like diuretic (hydrochlorothiazide, chlorthalidone, indapamide)

Triamterene is added as a potassium-sparing adjunct when:

A thiazide or loop diuretic is causing clinically significant hypokalemia despite dietary potassium advice
There is a clinical indication for potassium conservation (e.g., concurrent digoxin use where hypokalemia enhances digoxin toxicity)

💡 In current evidence-based hypertension management, spironolactone has largely superseded triamterene as the preferred potassium-sparing diuretic, particularly for resistant hypertension (PATHWAY-2 trial evidence). Triamterene retains a role when spironolactone is contraindicated (e.g., gynecomastia intolerance in men) or when aldosterone-independent potassium-sparing is specifically desired.

BP Target Guidance (Antihypertensive Class-Specific)

Based on Indian Guidelines on Hypertension (IGH-IV) and API/Cardiological Society of India (CSI) recommendations:

Population	Target BP
Uncomplicated hypertension	<140/90 mmHg
Hypertension with diabetes mellitus	<130/80 mmHg
Hypertension with CKD (with proteinuria)	<130/80 mmHg
Hypertension with CKD (without proteinuria)	<140/90 mmHg
Post-stroke (chronic phase)	<130/80 mmHg
Elderly (60–79 years)	<140/90 mmHg (flexible up to <150/90 in frail patients)
Very elderly (≥80 years)	<150/90 mmHg
Hypertension with established coronary artery disease	<130/80 mmHg (avoid diastolic <60 mmHg)

ℹ️ Triamterene, when used as part of an FDC with a thiazide, contributes to BP lowering — but the antihypertensive effect is primarily attributable to the thiazide component. Triamterene’s independent contribution to BP reduction is marginal.

Compelling Indications (Antihypertensive Class-Specific)

Triamterene does not have independent cardiovascular outcome data (no large RCTs demonstrating morbidity/mortality reduction). It has no specific “compelling indication” in the same sense as ACE inhibitors (post-MI, diabetic nephropathy), ARBs (heart failure), or spironolactone (resistant hypertension, heart failure with reduced EF).

The rationale for choosing triamterene is electrolyte preservation, not outcome superiority:

Consider when thiazide-induced hypokalemia is documented and persistent
Consider when concurrent digoxin therapy makes normokalaemia critical
Consider when spironolactone is not tolerated (gynecomastia, menstrual irregularity) and amiloride is not available

PRIMARY INDICATION 1: Hypertension — Adjunctive Therapy with Thiazide Diuretics

Classification: Primary / Approved in India

Triamterene is approved for use in hypertension in combination with thiazide diuretics. In Indian practice, it is most commonly prescribed as the FDC (triamterene 50 mg + benzthiazide 25 mg).

Dosing — Single-Ingredient Triamterene (when adding to an existing thiazide regimen):

Parameter	Details
Starting dose	50 mg once daily after the morning meal
Titration	May increase to 50 mg twice daily (after breakfast and after lunch) after 1–2 weeks if potassium-sparing effect inadequate, guided by serum potassium monitoring
Usual maintenance dose	50–100 mg/day in 1–2 divided doses
Maximum dose	Max 100 mg per dose; Max 200 mg per day (for hypertension indication — higher doses offer no additional antihypertensive or potassium-sparing benefit but increase adverse effect risk)

Dosing — FDC: Triamterene 50 mg + Benzthiazide 25 mg:

Parameter	Details
Starting dose	1 tablet once daily after the morning meal
Titration	May increase to 1 tablet twice daily (after breakfast and after lunch) after 2–4 weeks if BP target not achieved
Usual maintenance dose	1–2 tablets daily
Maximum dose	Max 1 tablet per dose; Max 2 tablets per day (triamterene 100 mg + benzthiazide 50 mg total daily)

Dosing — FDC: Triamterene 50 mg + Hydrochlorothiazide 25 mg:

Parameter	Details
Starting dose	1 capsule/tablet once daily after the morning meal
Titration	May increase to 1 capsule/tablet twice daily after 2–4 weeks
Usual maintenance dose	1–2 capsules/tablets daily
Maximum dose	Max 1 capsule per dose; Max 2 capsules per day

Duration: Indefinite for chronic hypertension management — ongoing treatment as long as the diuretic regimen is clinically indicated.

Mandatory Clinical Notes Checklist:

1. When to prefer this drug over alternatives:

(a) Clinical scenarios where triamterene has an advantage:

When a thiazide diuretic is indicated for hypertension AND the patient develops documented, persistent hypokalemia (K⁺ <3.5 mEq/L) despite dietary potassium supplementation — adding triamterene (or switching to a triamterene-thiazide FDC) is a reasonable approach to preserve potassium without stopping the thiazide
When the patient is on concurrent digoxin therapy — hypokalemia enhances digoxin toxicity, making potassium-sparing co-therapy particularly important
When spironolactone is not tolerated (gynecomastia in men, menstrual irregularity in premenopausal women, breast tenderness) — triamterene provides an aldosterone-independent potassium-sparing alternative without anti-androgenic effects
When amiloride (the other ENaC inhibitor) is not available — amiloride is the preferred ENaC inhibitor in many guidelines due to its better documented pharmacokinetics and safety profile, but its availability in India as a single-ingredient product is also limited

(b) This advantage makes triamterene an acceptable ALTERNATIVE, not a first-line agent. Spironolactone (for resistant hypertension) and amiloride (for ENaC blockade) are generally preferred when available.

vs Spironolactone: Spironolactone has outcome data for heart failure (RALES trial) and resistant hypertension (PATHWAY-2 trial); triamterene has neither. Spironolactone also acts via a different mechanism (MRA), addressing aldosterone-mediated pathology. Triamterene is preferred only when spironolactone’s anti-androgenic effects are intolerable.
vs Amiloride: Same mechanism class. Amiloride has more predictable PK (better bioavailability, less variable absorption, no significant hepatic metabolism). Amiloride does not cause crystalluria or nephrolithiasis. Amiloride is generally preferred when available. In India, however, amiloride + HCTZ FDCs may be more readily available than single-ingredient amiloride.
vs Oral potassium supplementation (KCl): Potassium supplements are an alternative approach to correcting thiazide-induced hypokalemia but require ongoing tablet burden, carry their own GI side effects, and provide no additional natriuretic benefit. Triamterene-thiazide FDC is more convenient and provides a sustained potassium-sparing effect.

2. When NOT to use even though technically indicated:

⛔ Do not use in patients already on ACE inhibitors/ARBs AND spironolactone/eplerenone — adding triamterene to this combination creates triple potassium-retaining therapy with very high hyperkalemia risk
⛔ Do not use in patients with baseline serum potassium ≥5.0 mEq/L
⛔ Do not use in patients with eGFR <30 mL/min (reduced efficacy + increased hyperkalemia risk)
⛔ Do not initiate in patients with history of triamterene-containing kidney stones
Avoid in patients with pre-existing folate deficiency, megaloblastic anaemia, or concurrent anti-folate therapy (methotrexate, trimethoprim) without folate supplementation

3. NLEM India status:
⚠️ Triamterene is NOT included in the current NLEM India (2022). Spironolactone (25 mg, 50 mg tablets) IS listed in NLEM under diuretics. Hydrochlorothiazide (12.5 mg, 25 mg) and furosemide (20 mg, 40 mg tablets; 10 mg/mL injection) are also NLEM-listed. Amiloride is listed in NLEM as an FDC with hydrochlorothiazide.

4. Typical time to expected clinical response:

Onset of diuretic/potassium-sparing effect: 2–4 hours after first dose
Steady-state potassium effect: 3–5 days of regular dosing
BP reduction (FDC with thiazide): 2–4 weeks for full antihypertensive effect
ℹ️ Do not assess antihypertensive efficacy before 4 weeks of regular use

5. Criteria for considering treatment failure and switching:

If serum potassium remains <3.5 mEq/L despite triamterene 200 mg/day + thiazide: consider switching to spironolactone (which is a more potent potassium-sparing agent) or adding oral KCl supplementation under close monitoring
If BP remains above target after 4–6 weeks of FDC at maximum dose: the FDC is inadequate as an antihypertensive strategy — add a first-line agent (ACE inhibitor/ARB or CCB) rather than further escalating the FDC dose
If renal function deteriorates (eGFR decline >25% or rising creatinine): reassess need for triamterene; discontinue if eGFR falls below 30 mL/min

6. Mandatory baseline investigations before starting:

Investigation	Grade
Serum potassium	MANDATORY — Do not start without knowing baseline K⁺. If K⁺ ≥5.0 mEq/L, do not initiate.
Serum creatinine + eGFR calculation	MANDATORY — Do not start if eGFR <30 mL/min.
Serum sodium	RECOMMENDED
Serum magnesium	RECOMMENDED (especially if concurrent digoxin use)
Blood urea nitrogen (BUN)	RECOMMENDED
Uric acid	OPTIONAL but helpful (triamterene may increase uric acid)
Complete blood count	RECOMMENDED (baseline for monitoring megaloblastic changes)
Blood glucose	RECOMMENDED (thiazide component may affect glucose)

7. Specialist initiation vs primary care prescribing:
The triamterene + benzthiazide FDC has been widely prescribed in Indian primary care for decades. Primary care prescribing is acceptable for uncomplicated mild-to-moderate hypertension with thiazide-induced hypokalemia. However:

Specialist input recommended if eGFR 30–60 mL/min
Specialist input recommended if concurrent ACE inhibitor/ARB use (hyperkalemia risk assessment)
Specialist input recommended in heart failure patients

8. Relevant Indian guideline source:

Indian Guidelines on Hypertension (IGH-IV, 2019) — positions thiazide/thiazide-like diuretics as first-line; potassium-sparing agents as adjuncts
API Textbook of Medicine (latest edition) — covers use of potassium-sparing diuretics in combination with thiazides
CSI (Cardiological Society of India) consensus statements

9. Key disease-specific safety warning:
⚠️ Hyperkalemia is the most clinically significant risk. The risk is amplified when triamterene is combined with ACE inhibitors, ARBs, potassium supplements, or used in patients with renal impairment, diabetes, or in the elderly. Life-threatening hyperkalemia (K⁺ >6.5 mEq/L) can occur insidiously. Monitor serum potassium within 1 week of initiation and at every dose change.

10. Common clinical scenarios where dose adjustment is needed:

eGFR 30–60 mL/min: Reduce maximum dose to 50 mg/day; increase potassium monitoring frequency to weekly
Concurrent ACE inhibitor or ARB: Reduce triamterene dose to 50 mg/day maximum; monitor K⁺ within 3–5 days of starting the combination
Elderly (≥60 years): Start at 25–50 mg/day; monitor K⁺ more frequently
Hepatic impairment (Child-Pugh A or B): Use with caution; reduce dose; monitor electrolytes closely

11. Common investigation misconception flag:
ℹ️ Serum potassium measured from a hemolysed blood sample gives a falsely elevated result. This is a common issue in Indian primary care settings where blood draw technique or delayed processing may cause in-vitro hemolysis. If an unexpectedly high potassium level is reported in a clinically stable patient on triamterene, repeat the sample with careful phlebotomy technique and prompt processing before making dose adjustments or discontinuing the drug.

First-Dose Hypotension Risk (Antihypertensive Class-Specific)

Triamterene has minimal first-dose hypotension risk when used as a single agent. The thiazide component of the FDC carries a modest risk of postural hypotension, particularly in:

Elderly patients
Volume-depleted patients (hot weather, inadequate fluid intake, concurrent illness)
Patients on concurrent antihypertensives

💡 Practical Indian context: Advise patients starting the FDC during Indian summer months (April–June) to maintain adequate fluid intake and rise slowly from sitting/lying. First dose is best taken after the morning meal.

Withdrawal / Rebound Risk (Antihypertensive Class-Specific)

No clinically significant rebound hypertension with triamterene discontinuation. However:

If the thiazide component of the FDC is also discontinued simultaneously, gradual BP rise will occur over days to weeks — not acute rebound
If triamterene is stopped but the thiazide is continued, serum potassium may decline over 3–7 days as the potassium-sparing effect wears off — monitor potassium and consider supplementation or alternative potassium-sparing agent

Abrupt discontinuation is generally safe. No tapering required.

Home BP Monitoring Guidance (Antihypertensive Class-Specific)

Standard home BP monitoring recommendations apply when triamterene is used as part of an antihypertensive regimen:

Recommend a validated, automated upper arm BP monitor
Target home BP: <135/85 mmHg (home values are typically 5 mmHg lower than clinic values)
Measure twice in the morning (before medication) and twice in the evening, record for ≥4 days before clinic review
Avoid wrist monitors; avoid measuring immediately after exercise, meals, or caffeine

PRIMARY INDICATION 2: Edema — Adjunctive Therapy with Loop or Thiazide Diuretics

Classification: Primary / Approved in India

Triamterene is approved for adjunctive management of edema associated with:

Congestive heart failure (CHF)
Hepatic cirrhosis with ascites
Nephrotic syndrome

Per the Combined Indication Rule: These three edematous conditions share identical triamterene dosing ranges, identical route (oral), identical frequency (once or twice daily), with differences primarily in severity-based dose selection, duration, and condition-specific precautions. They are therefore combined into a single dosing entry with condition-specific notes below.

Dosing — Single-Ingredient Triamterene (adjunct to loop or thiazide diuretics for edema):

Parameter	Details
Route	Oral
Starting dose	50 mg once daily after the morning meal (or 25 mg once daily in elderly or hepatic impairment)
Titration	May increase by 50 mg every 3–7 days based on potassium response and clinical edema reduction. Assess serum K⁺ before each dose increase.
Usual maintenance dose	100–200 mg/day in 1–2 divided doses (take after meals)
Maximum dose	Max 150 mg per dose; Max 300 mg per day
Duration	Ongoing for as long as diuretic therapy continues and potassium-sparing is required. Reassess periodically (every 3–6 months) whether the potassium-sparing component is still needed.

Condition-Specific Clinical Notes:

A. Congestive Heart Failure (CHF) — Edema:

1. When to prefer this drug over alternatives:

(a) Advantage scenario: Triamterene may be considered when loop diuretic–induced hypokalemia is persistent AND spironolactone is not tolerated (gynecomastia). In HFrEF, spironolactone or eplerenone are strongly preferred (RALES, EMPHASIS-HF outcome data) and triamterene is a distant alternative. In HFpEF, evidence for MRAs is emerging but triamterene has no specific outcome data.
(b) Not first-line for any HF scenario. An acceptable alternative ONLY when MRAs are contraindicated or not tolerated.
(c) vs Spironolactone: Spironolactone has mortality reduction data in HFrEF (RALES trial). Triamterene has no mortality data. Spironolactone also addresses aldosterone-mediated cardiac fibrosis — triamterene does not. Spironolactone is strongly preferred in all HF patients unless intolerant. vs Eplerenone: Selective MRA; less gynecomastia than spironolactone; outcome data in post-MI HF (EPHESUS) — preferred over triamterene. Availability and cost in India may be limiting. vs Amiloride: Same mechanism class; similar lack of HF outcome data; amiloride has better PK predictability.

2. When NOT to use:

⛔ Do not use as a substitute for spironolactone/eplerenone in HFrEF when these are tolerated
⛔ Do not use in acute decompensated heart failure (ADHF) — parenteral diuretics required; triamterene is for stable, chronic HF-related edema only
⛔ Do not use if serum K⁺ ≥5.0 mEq/L or eGFR <30 mL/min

4. Typical time to expected clinical response: Edema reduction: days to 1–2 weeks. Potassium stabilization: 3–5 days.

5. Treatment failure criteria: If edema persists or worsens despite triamterene 200–300 mg/day + adequate loop diuretic doses, reassess volume status (weigh daily), adherence, dietary sodium, and consider nephrology/cardiology referral for diuretic resistance strategies.

9. Key safety warning:
⚠️ Triple RAAS blockade risk: Many HF patients are already on ACE inhibitor/ARB + spironolactone. Adding triamterene to this regimen is strongly discouraged — life-threatening hyperkalemia risk. If triamterene is used alongside an ACE inhibitor or ARB (without spironolactone), mandate serum K⁺ monitoring at 3 days, 1 week, 2 weeks, and monthly thereafter.

B. Hepatic Cirrhosis with Ascites:

1. When to prefer this drug over alternatives:

(a) Advantage scenario: In cirrhotic ascites, spironolactone is the established first-line diuretic (acts against the secondary hyperaldosteronism driving sodium retention). Triamterene has a very limited role. It may be considered only when spironolactone causes intolerable gynecomastia or breast pain AND eplerenone is unavailable/unaffordable AND amiloride is also unavailable.
(b) NOT first-line. A last-resort alternative among potassium-sparing diuretics for this condition.
(c) vs Spironolactone: Spironolactone addresses the pathophysiological mechanism (hyperaldosteronism) directly and is the established standard per API Textbook and AASLD/EASL guidelines extrapolated to Indian practice. vs Amiloride: Neither has outcome data in cirrhosis, but amiloride avoids the crystalluria/nephrolithiasis risk.

2. When NOT to use:

⛔ Do not use as first-line diuretic for cirrhotic ascites — spironolactone is the standard
⛔ Do not use in patients with hepatorenal syndrome (eGFR will be critically low)
⛔ Do not use in severe hepatic impairment (Child-Pugh C) — impaired hepatic metabolism of triamterene

9. Key safety warning:
⚠️ Megaloblastic anaemia risk: Cirrhotic patients often have pre-existing folate deficiency. Triamterene’s weak DHFR inhibitory activity may unmask or worsen folate deficiency — monitor CBC and consider folate supplementation.

⚠️ Crystalluria risk amplified: Patients with cirrhosis may have concentrated, acidic urine — increasing the risk of triamterene crystal deposition.

C. Nephrotic Syndrome:

1. When to prefer this drug over alternatives:

(a) Advantage scenario: In nephrotic syndrome, loop diuretics (furosemide) are the mainstay for edema management; thiazides may be added for diuretic resistance (sequential nephron blockade). Triamterene may be added if hypokalemia develops during aggressive diuresis. However, spironolactone (which also reduces proteinuria via MRA effect) is generally preferred.
(b) Not first-line. An acceptable alternative only when spironolactone is not tolerated.
© vs Spironolactone: Spironolactone has potential antiproteinuric benefit via aldosterone blockade; triamterene does not.

2. When NOT to use:

⛔ Do not use if renal function is significantly impaired (common in nephrotic syndrome with advancing disease)
⛔ Do not use if potassium is ≥5.0 mEq/L
⛔ Use with particular caution given the already elevated nephrolithiasis risk in nephrotic syndrome (volume contraction + concentrated urine) — triamterene crystalluria adds to this risk

6. Baseline investigations: Same as Primary Indication 1, plus: 24-hour urine protein (or uPCR) and serum albumin — both affect interpretation of drug protein binding and volume of distribution.

10. Dose adjustment scenario: In nephrotic syndrome with hypoalbuminemia, diuretic delivery to the tubule is altered. Triamterene’s efficacy may be reduced. Higher doses may be needed but increase toxicity risk — refer to nephrology.

General Mandatory Clinical Notes (applicable to all three edematous conditions):

3. NLEM India status: Triamterene is NOT in NLEM India (2022).

6. Mandatory baseline investigations: Same as Primary Indication 1 table (serum K⁺ MANDATORY, serum creatinine + eGFR MANDATORY, Na⁺, Mg²⁺, BUN, CBC RECOMMENDED).

7. Specialist initiation vs primary care: Specialist initiation recommended for all edematous conditions — CHF management by cardiologist, cirrhotic ascites by hepatologist/gastroenterologist, nephrotic syndrome by nephrologist. Primary care physicians may continue maintenance therapy once stabilised.

8. Relevant Indian guideline source: API Textbook of Medicine (latest edition) — diuretic management in heart failure, cirrhosis, nephrotic syndrome.

11. Common investigation misconception flag:
ℹ️ Spot urine potassium (single sample) is often ordered to assess potassium homeostasis during diuretic therapy but is unreliable without concurrent urine creatinine measurement. A urine potassium-to-creatinine ratio is more informative. If laboratory support for this is unavailable, rely on serial serum potassium measurements.

Orthostatic BP Check (Antihypertensive Class-Specific)

Recommended at baseline and during titration, particularly in:

Elderly patients (≥60 years)
Patients on multiple antihypertensives
Patients with diabetes (autonomic neuropathy risk)
Patients with hepatic cirrhosis (vasodilation, hypoalbuminemia, reduced effective circulating volume)

Technique: Measure BP supine → standing at 1 minute and 3 minutes. A systolic drop ≥20 mmHg or diastolic drop ≥10 mmHg indicates orthostatic hypotension.

SECONDARY INDICATIONS — Adults Only (Off-label)

Secondary Indication 1: Liddle Syndrome

OFF-LABEL but accepted standard practice — triamterene (or amiloride) is the specific pathophysiology-directed treatment for this rare autosomal dominant disorder of constitutive ENaC activation.

ℹ️ Liddle syndrome is an ultra-rare genetic cause of early-onset hypertension with hypokalemic metabolic alkalosis, low renin, and low aldosterone. The underlying mutation causes gain-of-function of ENaC in the collecting duct. Direct ENaC blockers (triamterene, amiloride) are the treatment of choice — MRAs (spironolactone) are ineffective because the defect is downstream of aldosterone receptor signaling.

Parameter	Details
Starting dose	50 mg twice daily
Titration	Increase by 50 mg/day every 1–2 weeks guided by BP and serum potassium
Usual maintenance dose	100–200 mg/day in 2 divided doses
Maximum dose	Max 150 mg per dose; Max 300 mg per day
Duration	Lifelong therapy
Specialist only?	Yes — diagnosis and initiation by endocrinologist/nephrologist with experience in monogenic hypertension

Evidence basis: Pathophysiology-directed therapy. No RCTs (disease is too rare), but strong mechanistic rationale and established expert consensus.

Level of evidence quality: Moderate (no RCTs possible; supported by pathophysiological mechanism, case series, and universal expert consensus — treatment of choice by mechanism).

ℹ️ Indian context: Liddle syndrome is underdiagnosed in India. Consider in young patients (<30 years) with hypertension, hypokalemia, metabolic alkalosis, suppressed aldosterone AND renin, who do not respond to spironolactone. Genetic testing (SCNN1B, SCNN1G mutations) is available at select centres (AIIMS, CMC Vellore, SGPGI Lucknow).

Secondary Indication 2: Lithium-Induced Nephrogenic Diabetes Insipidus (NDI)

OFF-LABEL — triamterene has been used to reduce polyuria in lithium-induced NDI.

ℹ️ Mechanism: ENaC blockade by triamterene reduces luminal sodium entry in the collecting duct. Since lithium enters principal cells partly through ENaC (replacing Na⁺), blocking ENaC reduces intracellular lithium accumulation — potentially reducing lithium’s interference with AQP2 (aquaporin-2) and thus partially restoring concentrating ability. However, amiloride is the far better-studied agent for this indication.

Parameter	Details
Starting dose	50 mg twice daily
Titration	Guided by urine output and serum electrolytes
Usual maintenance dose	100–200 mg/day
Maximum dose	Max 100 mg per dose; Max 200 mg per day
Duration	As long as lithium therapy continues and NDI symptoms persist
Specialist only?	Yes — psychiatrist + nephrologist collaboration recommended

Evidence basis: Mechanism-based rationale extrapolated from amiloride data. Very limited direct triamterene data; amiloride is far preferred.

Level of evidence quality: Weak (case reports and expert opinion; amiloride data extrapolated)

⚠️ Important: Amiloride is the preferred ENaC blocker for lithium-induced NDI and has stronger supporting evidence. Triamterene should be considered only when amiloride is unavailable. Monitor lithium levels — reduced ENaC-mediated lithium reabsorption may alter lithium clearance (though the effect is modest and unpredictable).

Secondary Indication 3: Cystic Fibrosis — Adjunctive Mucolytic (Experimental/Research Context)

OFF-LABEL — NOT standard practice

ℹ️ Triamterene and amiloride have been explored as inhaled agents to block ENaC-mediated excessive sodium (and water) absorption from the airway surface liquid (ASL) in cystic fibrosis — aiming to restore ASL hydration and mucociliary clearance. This remains largely experimental. Inhaled amiloride clinical trials showed inconsistent results. Triamterene has even less clinical data for this use. This is noted for completeness only and is NOT recommended for clinical prescribing.

Level of evidence quality: Very weak (preclinical/early clinical research; no validated dosing for this route/indication).

MISSED DOSE / DELAYED DOSE GUIDANCE

Dosing Frequency	Guidance
Once-daily dosing	If <12 hours late: Take the missed dose as soon as remembered, with food. If >12 hours late (i.e., closer to the next scheduled dose): Skip the missed dose entirely. Take the next dose at the usual time. Never double the dose.
Twice-daily dosing	If <6 hours late: Take the missed dose as soon as remembered, with food. If >6 hours late: Skip the missed dose. Take the next dose at the usual time. Never double the dose.
PRN use	Not applicable — triamterene is used on a regular schedule, not PRN.

Additional Missed Dose Guidance:

Triamterene does NOT have a narrow therapeutic index in the traditional sense, but its potassium-sparing effect means that erratic dosing can cause fluctuations in serum potassium. Consistent, regular dosing is preferred.
A single missed dose is unlikely to cause clinically significant potassium loss.
Multiple consecutive missed doses (≥3 days): If triamterene is held for ≥3 days while the thiazide or loop diuretic is continued, serum potassium may drop — especially in patients previously documented to have thiazide-induced hypokalemia. Consider checking serum potassium when resuming.
Can the drug be resumed at previous dose after a gap? Yes — triamterene can be resumed at the previous maintenance dose after a brief interruption (<1 week) without re-titration. For interruptions >1 week, resume at the starting dose and recheck serum potassium within 3–5 days.

Prolonged Non-Adherence / Drug Holiday Guidance:

No rebound effect upon discontinuation. Abrupt stopping does not cause withdrawal symptoms or rebound hypertension.
Upon discontinuation, the potassium-sparing effect dissipates within 1–2 days (based on half-life of active metabolite).
If the patient has been off triamterene for >1 week, check serum potassium before resuming to establish a new baseline.
No immunogenicity concerns (not a biologic).

RECONSTITUTION / ADMINISTRATION QUICK REFERENCE (For Nurses & Clinical Staff)

Not applicable — triamterene is available only in oral formulations (capsules, tablets). There is no injectable, inhaled, or topical formulation.

Oral Administration Notes:

Parameter	Details
Take with food	✔ ALWAYS take with or immediately after meals. This significantly increases bioavailability and reduces GI irritation. Fasting administration reduces absorption and increases inter-individual variability.
Can the tablet/capsule be crushed or opened?	Standard triamterene tablets: may be crushed if the patient has difficulty swallowing, though this is not a standard recommendation. Capsules: may be opened and contents mixed with a small amount of soft food (applesauce, curd/dahi) for patients with swallowing difficulty. There is no modified-release formulation — so crushing does not alter the release profile. However, verify with the specific manufacturer’s guidance.
Enteral tube compatibility	Tablets may be crushed and dispersed in water for administration via nasogastric or PEG tube. Flush with 30 mL water before and after. The drug’s poor water solubility may cause incomplete dissolution — flush well.
Timing of administration	Take the dose(s) in the morning and/or early afternoon (not in the evening or at bedtime) to avoid nocturia. For once-daily dosing: after breakfast. For twice-daily dosing: after breakfast and after lunch.
Interaction with specific foods	No specific food restriction other than the general requirement to take with food. However, avoid excessive intake of potassium-rich foods (bananas, coconut water, oranges, dried fruits, potatoes, spinach) while on triamterene — this adds to the potassium-sparing effect.

Storage:

Parameter	Details
Before opening	Store at room temperature (below 30°C). Protect from light and moisture.
After opening (multi-dose container)	Use within the manufacturer-specified period. In hot and humid Indian conditions, ensure the container is tightly closed after each use.
Hot-climate note (India-specific)	In regions where ambient temperatures regularly exceed 35°C (common April–June across most of India), store in the coolest, driest part of the house (not in the kitchen or bathroom). Do not refrigerate unless manufacturer specifically advises.

PAEDIATRIC DOSING (Specialist Only)

⚠️ All paediatric use of triamterene should be under specialist supervision — paediatric nephrologist, paediatric cardiologist, or paediatric endocrinologist as appropriate.

General Notes

Parameter	Details
Overall paediatric evidence base	Limited. Triamterene has been used in paediatric practice for decades, but formal paediatric pharmacokinetic studies and RCTs are sparse. Dosing recommendations are largely extrapolated from adult data, clinical experience, and expert consensus.
Safety monitoring requirements specific to paediatrics	Serum potassium is MANDATORY before initiation, at 3–5 days, at 1 week, at 1 month, and then at least every 3 months during ongoing therapy. More frequent monitoring in younger children and neonates. Serum creatinine/eGFR, sodium, and CBC should be checked at baseline and periodically. Growth monitoring (height, weight) at each visit — chronic diuretic use may affect growth indirectly via nutritional effects and electrolyte disturbances.
Minimum age	No absolute minimum age established. Used in infants and children of all ages for specific indications (Liddle syndrome, potassium-sparing adjunct). However, safety data in children <6 years is very limited, and use below this age requires specialist justification.
Minimum weight	No formal minimum weight established. Weight-based dosing (mg/kg) applies to all weight categories. Exercise extreme caution below 10 kg due to limited data and narrow margin of safety.
Formulation suitability for children	⚠️ No commercially available paediatric liquid formulation in India. This is a significant practical barrier. The available 50 mg and 100 mg capsules/tablets are designed for adult dosing. For young children requiring doses <50 mg, extemporaneous compounding (capsule contents mixed with vehicle) or tablet fractions are needed. Discuss with hospital pharmacy for preparation of a suspension. Triamterene powder is poorly water-soluble, which complicates suspension preparation.
Palatability	The drug has a bitter taste. If capsule contents are mixed with soft food (curd/dahi, mashed banana, applesauce, honey for children >1 year), palatability improves. Mixing with a small volume of flavoured syrup base may be used in extemporaneous preparations.
Age-specific PK differences	Neonates and young infants have immature renal tubular function and reduced GFR — triamterene and its active metabolite are cleared more slowly, increasing both duration of action and risk of hyperkalemia. Hepatic metabolism (hydroxylation and sulfation) is also immature in neonates and infants <6 months, leading to higher parent drug levels. By age 2–3 years, hepatic and renal maturation approaches adult capacity per kg, and standard weight-based dosing applies. In adolescents (≥12 years or ≥40 kg), adult dosing may be used.

Dosing Method

Priority	Method	Applicability
1st	Weight-based (mg/kg)	✔ Standard method for all paediatric triamterene dosing
2nd	BSA-based (mg/m²)	Not standard for triamterene
3rd	Age-based	Only when weight is unknown — not preferred
4th	Fixed dosing	Not applicable

Adolescent Transition

Children ≥12 years or ≥40 kg: Use adult dosing (50–200 mg/day in 1–2 divided doses). Maximum adult ceiling doses apply. No separate adolescent dosing tier needed.

Neonatal Dosing

Neonatal use — NICU supervision only

⚠️ Triamterene use in neonates (<28 days of life) is exceptional and should be undertaken only under neonatologist/paediatric nephrologist supervision. The drug is NOT a preferred agent for neonatal conditions. Its use in this age group is limited almost exclusively to:

Genetically confirmed Liddle syndrome presenting neonatally (extremely rare)
Severe, refractory hypokalemia from loop/thiazide diuretics in neonatal ICU settings when amiloride and spironolactone are unavailable

Neonatal PK Considerations:

Factor	Neonatal Impact
GFR	Markedly reduced (term neonate GFR ~20–30 mL/min/1.73 m²; preterm even lower) → reduced renal clearance of active metabolite → prolonged effect and hyperkalemia risk
Hepatic metabolism	Immature hydroxylation and sulfation → reduced metabolite formation → higher parent drug levels with unpredictable PK
Protein binding	Reduced albumin levels (especially preterm) → higher free drug fraction
Renal tubular ENaC expression	Neonatal ENaC expression and aldosterone responsiveness differ from adults → pharmacodynamic response may vary

Neonatal Dosing (Extrapolated — Limited Data):

Parameter	Details
Term neonates	1–2 mg/kg/day in 1–2 divided doses. Start at the lower end (1 mg/kg/day). Monitor serum K⁺ every 12–24 hours during initiation.
Preterm neonates	0.5–1 mg/kg/day once daily. Extremely cautious approach. Monitor serum K⁺ at least every 12 hours. eGFR is very low — risk of severe metabolite accumulation.
Maximum neonatal dose	Max 2 mg/kg/day. Do not exceed without paediatric nephrology guidance.
Route	Oral only. Extemporaneous suspension needed — capsule contents dispersed in a small volume of oral vehicle.
Duration	Shortest possible. Reassess need within 48–72 hours.

⚠️ Based on extrapolation from limited pharmacokinetic data; no validated neonatal dosing regimen exists. The drug is NOT a preferred agent for neonatal potassium-sparing indications — spironolactone has substantially more neonatal experience. Triamterene is a last-resort option when spironolactone and amiloride are both unavailable.

Gestational age considerations:

Preterm (<37 weeks): Renal and hepatic maturation is significantly delayed. GFR may be <10 mL/min/1.73 m² in extremely preterm infants. Use only if absolutely necessary, at the lowest dose, with intensive electrolyte monitoring.
Term (≥37 weeks): Renal function improves rapidly over the first 1–2 weeks of life but remains substantially below older infant levels. Start at 1 mg/kg/day.

Primary Indications — Paediatric

Paediatric Primary Indication 1: Hypokalemia Prevention — Adjunctive to Thiazide or Loop Diuretics

Classification: Primary / Approved — extrapolated from approved adult indication

This is the most common paediatric use of triamterene: as a potassium-sparing adjunct when children are on chronic thiazide or loop diuretic therapy for conditions such as:

Congenital heart disease (post-cardiac surgery diuretic regimens)
Bronchopulmonary dysplasia (BPD) in premature infants requiring chronic furosemide
Nephrotic syndrome (diuretic-induced hypokalemia)
Other chronic edematous states

Weight-Based Dosing Table:

Weight Category	Starting Dose	Titration	Usual Maintenance Dose	Maximum Dose	Clinical Notes
<10 kg	1 mg/kg/day once daily	Increase by 0.5 mg/kg/day every 5–7 days if K⁺ remains low; check K⁺ before each increase	1–2 mg/kg/day in 1–2 divided doses	Max 2 mg/kg/day	Extemporaneous preparation needed. Very limited data. Specialist supervision essential.
10–20 kg	1–2 mg/kg/day once daily	Increase by 1 mg/kg/day every 5–7 days	2–4 mg/kg/day in 1–2 divided doses	Max 4 mg/kg/day; absolute max 100 mg/day	Can use half a 50 mg capsule/tablet content (25 mg) as a practical starting dose in a 10–12 kg child
20–40 kg	2 mg/kg/day once daily or 50 mg once daily (whichever is lower)	Increase by 25–50 mg every 5–7 days	2–4 mg/kg/day in 1–2 divided doses	Max 4 mg/kg/day; absolute max 200 mg/day	Can use standard 50 mg units
≥40 kg	50 mg once daily	As per adult titration	50–200 mg/day in 1–2 divided doses	Max 200 mg/day (adult ceiling for this indication)	Adult dosing applies

All doses to be taken with or after meals.

Mandatory Clinical Notes Checklist (Paediatric-Specific):

1. When to prefer triamterene over alternatives in children:

(a) Advantage scenario: When spironolactone causes gynaecomastia in pubertal boys (though this is less common at typical paediatric doses), or when amiloride is unavailable. In BPD neonates on chronic furosemide, spironolactone is the preferred potassium-sparing agent (more neonatal experience); triamterene is a distant alternative.
(b) NOT first-line. Acceptable alternative only when spironolactone or amiloride are unavailable or not tolerated.
© vs Spironolactone: Spironolactone has far more paediatric experience, better-documented safety profile in children, and available liquid formulations in some centres. vs Amiloride: Same mechanism class, better PK predictability, no crystalluria risk — preferred when available.

2. When NOT to use in children:

⛔ Do not use in neonates unless spironolactone and amiloride are truly unavailable (see Neonatal section above)
⛔ Do not use in children with eGFR <30 mL/min/1.73 m²
⛔ Do not use if baseline serum K⁺ ≥5.5 mEq/L (paediatric threshold — slightly higher than adult due to normal age-specific values in younger children)
⛔ Do not use in children with known folate deficiency without concurrent folate supplementation

3. NLEM India status: Triamterene is NOT in NLEM. Spironolactone (25 mg, 50 mg) IS in NLEM.

4. Time to expected response: Potassium-sparing effect: 2–5 days. Diuretic effect (modest): 1–3 days.

5. Treatment failure criteria: If serum K⁺ remains <3.5 mEq/L despite maximum tolerated triamterene dose + ongoing diuretic, switch to spironolactone (if not already tried) or add oral potassium supplementation under specialist guidance.

6. Mandatory baseline investigations:

Serum K⁺ — MANDATORY
Serum creatinine + eGFR (Schwartz formula for children) — MANDATORY
Serum Na⁺, Mg²⁺ — RECOMMENDED
CBC — RECOMMENDED (baseline for folate/megaloblastic monitoring)
Urinalysis — RECOMMENDED (baseline for crystalluria monitoring)

7. Specialist initiation:Yes — all paediatric use should be initiated by a specialist. Maintenance prescriptions may be continued by paediatricians with appropriate monitoring.

8. Indian guideline source: IAP guidelines on diuretic use in children (general principles); specific paediatric nephrology and cardiology protocols from AIIMS, CMC Vellore, SGPGI. No specific IAP guideline dedicated to triamterene in children.

9. Key safety warning:
⚠️ Hyperkalemia monitoring in children is MORE critical than in adults because:

Normal serum potassium ranges in neonates and infants are higher than adults (up to 5.5–6.0 mEq/L in the first weeks of life)
Hemolyzed samples are common in paediatric phlebotomy → false elevations
Symptoms of hyperkalemia may be non-specific in young children (irritability, feeding difficulty, bradycardia)
ECG monitoring is recommended at potassium ≥5.5 mEq/L

10. Dose adjustment scenarios:

If eGFR 30–60 mL/min/1.73 m²: Use 50% of standard dose with weekly K⁺ monitoring
If concurrent ACE inhibitor (e.g., enalapril in paediatric heart failure): Use minimum effective triamterene dose, check K⁺ within 3 days of starting the combination

Paediatric Primary Indication 2: Edema — Adjunctive Therapy

Dosing is identical to Paediatric Primary Indication 1 (same mg/kg range, route, frequency). The only difference is the clinical context — edema reduction rather than isolated hypokalemia prevention. As per the Combined Indication Rule, no separate dosing table is needed. Refer to the weight-based dosing table above.

Condition-specific notes:

In congenital heart disease with edema, diuretic combinations are often managed by paediatric cardiologists with specific institutional protocols
In nephrotic syndrome, the nephrologist’s protocol takes precedence; triamterene’s role is adjunctive and limited
Duration: Ongoing while the diuretic regimen continues; reassess need at each clinic visit

Secondary Indications — Paediatric (Off-label)

Paediatric Secondary Indication 1: Liddle Syndrome (Paediatric Presentation)

OFF-LABEL but accepted standard practice — direct ENaC blockade is the pathophysiology-directed treatment.

ℹ️ Liddle syndrome may present in childhood or adolescence with hypertension, hypokalemia, and metabolic alkalosis. Genetic confirmation (SCNN1B/SCNN1G mutations) is recommended before committing to lifelong ENaC blocker therapy.

Weight Category	Starting Dose	Titration	Maintenance Dose	Maximum Dose
<20 kg	1–2 mg/kg/day in 2 divided doses	Increase by 1 mg/kg/day every 1–2 weeks; guided by BP and K⁺	2–4 mg/kg/day in 2 divided doses	Max 4 mg/kg/day; absolute max 200 mg/day
20–40 kg	50 mg/day in 1–2 divided doses	Increase by 25–50 mg every 1–2 weeks	100–200 mg/day in 2 divided doses	Max 4 mg/kg/day; absolute max 300 mg/day
≥40 kg	50 mg twice daily	As per adult Liddle syndrome dosing	100–200 mg/day in 2 divided doses	Max 300 mg/day

Duration: Lifelong. This is a genetic disorder — treatment cannot be discontinued.

Specialist only? Yes — paediatric nephrologist or endocrinologist with experience in monogenic hypertension.

Evidence basis: Mechanism-based; universal expert consensus. No paediatric RCTs (disease is ultra-rare). Case series from paediatric nephrology centres support efficacy.

Level of evidence quality: Moderate (adult case series with paediatric PK extrapolation; pathophysiological rationale is unquestionable)

Paediatric-specific notes:

Amiloride is generally preferred over triamterene in children for Liddle syndrome due to better PK predictability and absence of crystalluria risk — but availability in India may dictate the choice
Spironolactone is INEFFECTIVE for Liddle syndrome — do not substitute
Long-term monitoring: BP, K⁺, renal function, CBC (folate), and urinalysis (crystalluria) at each clinic visit (every 3–6 months)
Transition to adult services should include explicit handover of the genetic diagnosis, lifelong treatment plan, and reproductive counselling (autosomal dominant inheritance)

Paediatric Secondary Indication 2: Cystic Fibrosis–Related Pseudo-Bartter Syndrome

OFF-LABEL — limited evidence

ℹ️ Children with cystic fibrosis may develop electrolyte disturbances mimicking Bartter syndrome (hyponatremia, hypokalemia, hypochloremic metabolic alkalosis) due to excessive sweat electrolyte losses, particularly in hot climates. While the primary management is aggressive salt and fluid replacement, triamterene has occasionally been used adjunctively to limit renal potassium wasting. This is a niche, specialist-only use.

Parameter	Details
Dose	2 mg/kg/day in 1–2 divided doses
Maximum dose	Max 4 mg/kg/day; absolute max 200 mg/day
Duration	Short-term during acute episodes; ongoing only if recurrent and refractory to salt supplementation alone
Specialist only?	Yes — paediatric pulmonologist or paediatric nephrologist

Evidence basis: Case reports, expert opinion. No paediatric RCTs.

Level of evidence quality: Weak (case series, expert opinion)

⚠️ Salt and fluid replacement remains the MAINSTAY of management. Triamterene should not be used as a substitute for adequate NaCl supplementation.

No Other Established Paediatric Off-Label Indications

If the drug is used in a paediatric scenario not covered above: “No established paediatric dosing. Use only under specialist supervision.”

RENAL ADJUSTMENT

eGFR Formula Specification:

Dosing adjustments in the table below are based on eGFR by CKD-EPI formula for adults (≥18 years). Original pharmacokinetic studies used Cockcroft-Gault creatinine clearance (CrCl) — values may differ from CKD-EPI eGFR, particularly in elderly patients (Cockcroft-Gault tends to give lower values in the elderly due to inclusion of age and weight in the calculation). For clinical decision-making:

If CrCl by Cockcroft-Gault < 30 mL/min → triamterene is contraindicated regardless of CKD-EPI eGFR
In borderline cases (CKD-EPI eGFR 30–45 mL/min), calculate CrCl by Cockcroft-Gault as a cross-check before initiating triamterene

For paediatric renal adjustment, use the Schwartz formula for eGFR estimation.

Pharmacokinetic Rationale for Renal Adjustment:

The active metabolite (p-hydroxytriamterene sulfate) is primarily cleared by renal excretion — both glomerular filtration and active tubular secretion via OAT1/OAT3 transporters. In renal impairment:

Metabolite accumulation → sustained and exaggerated potassium-sparing effect → hyperkalemia risk
Reduced delivery of drug to the tubular lumen → paradoxically reduced diuretic efficacy
Net effect: less therapeutic benefit + more toxicity — a particularly unfavourable combination
Crystalluria and stone risk are amplified by concentrated, low-volume urine common in CKD
Triamterene’s metabolites are poorly dialysable — haemodialysis does not effectively correct drug accumulation

Renal Adjustment Table — Adults:

eGFR (mL/min)	Dose Adjustment	Formulation Notes	Monitoring	Notes
>60	No adjustment required. Standard dosing applies.	Standard capsules/tablets or FDC	Serum K⁺ at baseline, 1 week, then every 3 months	Standard of care
45–60	Use with caution. Maximum dose 100 mg/day. Start at 50 mg once daily.	Standard formulations acceptable	Serum K⁺ at baseline, 3–5 days, 1 week, 2 weeks, then monthly for 3 months, then every 2–3 months	Risk of hyperkalemia begins to increase meaningfully. Avoid concurrent ACE inhibitor/ARB if possible; if unavoidable, increase K⁺ monitoring to weekly for the first month.
30–45	⚠️ Use only if clearly indicated and alternatives (spironolactone, amiloride) are unavailable/contraindicated. Maximum dose 50 mg/day. Start at 25 mg once daily (half a 50 mg capsule/tablet — may require splitting).	Consider using single-ingredient triamterene rather than FDC for more precise dose control	Serum K⁺ at baseline, 48 hours, then twice weekly for 2 weeks, then weekly for 1 month, then every 2 weeks	Specialist supervision recommended. Reduced efficacy and increased toxicity risk. Most patients in this range should be managed with alternative potassium-sparing strategies. Concurrent ACE inhibitor/ARB use is strongly discouraged.
15–30	⛔ Generally avoid. If use is absolutely necessary (e.g., Liddle syndrome with CKD — rare scenario), use only under specialist nephrologist supervision with inpatient-level electrolyte monitoring. Maximum dose 25 mg once daily or every other day.	Single-ingredient only; avoid FDC	Serum K⁺ at least daily during initiation; transition to twice weekly once stable	Efficacy markedly reduced. Hyperkalemia risk very high. Document clinical justification.
<15 (non-dialysis)	⛔ Contraindicated. Do not use.	—	—	No meaningful diuretic efficacy. Unacceptable hyperkalemia risk.
Haemodialysis	⛔ Contraindicated. Do not use. Triamterene and metabolites are poorly removed by haemodialysis.	—	—	No diuretic effect in anuric/oliguric HD patients. Hyperkalemia hazard between dialysis sessions. No supplemental post-HD dose warranted.
Peritoneal dialysis	⛔ Contraindicated. Do not use. Not significantly cleared by peritoneal dialysis.	—	—	Same rationale as HD.
CRRT	Data limited. Generally avoid. If used in exceptional circumstances (Liddle syndrome in ICU), specialist intensivist/nephrologist decision with continuous electrolyte monitoring.	—	Continuous or 4–6 hourly K⁺ monitoring	CRRT provides some metabolite clearance, but data are insufficient to provide dosing guidance.

Formulation-Specific Renal Adjustment:

Triamterene is not available in modified-release (MR/ER/CR) formulations — all marketed formulations are immediate-release. Therefore, no MR vs IR formulation switching guidance is applicable.

However, regarding FDC vs single-ingredient:

When eGFR is 30–45 mL/min, the FDC (triamterene + thiazide) may be problematic because:
- The thiazide dose cannot be independently titrated
- Thiazide efficacy also declines below eGFR 30 mL/min (though remains partially effective above this threshold)
- If the patient needs to reduce triamterene to 25 mg/day, the FDC tablet cannot be easily halved to achieve this
Recommendation: Switch from FDC to separate, individually-dosed components when eGFR <45 mL/min to allow independent dose titration.

Augmented Renal Clearance (ARC):

For the very few scenarios where triamterene might be considered in ICU patients with ARC (CrCl >130 mL/min — seen in young, non-elderly patients with sepsis, trauma, or burns):

ARC would increase renal clearance of the active metabolite → reduced drug effect → potentially requiring higher-than-usual doses
However, triamterene has virtually no role in ICU diuretic management (IV furosemide is the standard)
Practical relevance: Nil. This drug is not used in ICU settings in any meaningful way.

Paediatric Renal Adjustment:

Schwartz eGFR (mL/min/1.73 m²)	Adjustment
>60	Standard weight-based dosing
30–60	Use 50% of standard weight-based dose; weekly K⁺ monitoring; specialist supervision
<30	⛔ Avoid — same rationale as adults

HEPATIC ADJUSTMENT

Pharmacokinetic Rationale:

Triamterene undergoes extensive first-pass hepatic metabolism (hydroxylation → sulfation). The parent drug has a high hepatic extraction ratio. In hepatic impairment:

Reduced first-pass metabolism → increased oral bioavailability of the parent drug → higher systemic parent drug levels
Delayed metabolite formation → unpredictable ratio of parent drug to active metabolite
In cirrhosis with hypoalbuminemia, reduced protein binding → higher free drug fraction → enhanced pharmacological effect per unit of total drug
In cirrhosis with ascites, increased volume of distribution may partially offset the increased bioavailability — net pharmacokinetic effect is complex and unpredictable
Folate stores are commonly depleted in chronic liver disease (especially alcoholic liver disease) → triamterene’s weak DHFR inhibition may precipitate megaloblastic anaemia more readily

Hepatic Adjustment Table:

Child-Pugh Classification	Dose Adjustment	Clinical Notes
Mild impairment (Child-Pugh A)	Use with caution. Start at the lower end of the dose range (50 mg once daily for adult indications). Maximum dose: 100 mg/day. Titrate slowly — at least 1-week intervals between dose increases.	Monitor serum K⁺ at baseline, 3–5 days, 1 week, then monthly. Monitor liver function (ALT, AST, bilirubin) at baseline and periodically. Hepatic metabolism is mildly impaired — modest increase in drug exposure expected.
Moderate impairment (Child-Pugh B)	⚠️ Use only if clearly indicated and alternatives are contraindicated. Start at 25 mg once daily (half of 50 mg capsule/tablet). Maximum dose: 50 mg/day. Do not titrate faster than every 2 weeks.	Specialist supervision recommended (hepatologist or gastroenterologist). Higher free drug fraction due to hypoalbuminemia — pharmacological effect per total drug level is amplified. Folate supplementation recommended. Monitor for: hyperkalemia, crystalluria (concentrated acidic urine is common in cirrhosis), and megaloblastic changes (CBC at baseline, 1 month, 3 months).
Severe impairment (Child-Pugh C)	⛔ Avoid. Do not use triamterene in severe hepatic impairment.	Risk of unpredictable drug accumulation, hyperkalemia, and hepatic encephalopathy precipitation (electrolyte disturbances). If a potassium-sparing diuretic is needed in severe cirrhosis, spironolactone (which is the first-line agent for cirrhotic ascites and is NOT dependent on hepatic metabolism in the same way) should be used under specialist supervision — though even spironolactone requires caution in Child-Pugh C.

Formulation-Specific Hepatic Adjustment:

All marketed triamterene formulations are immediate-release. No MR formulation exists. Therefore, no MR vs IR formulation switching guidance is applicable in hepatic impairment.

Regarding FDC use in hepatic impairment:

In Child-Pugh A: FDC (triamterene 50 mg + benzthiazide 25 mg or HCTZ 25 mg) may be used with the standard caution — essentially equivalent to a single FDC tablet daily at maximum
In Child-Pugh B: FDC is not recommended because independent dose reduction of the triamterene component to 25 mg/day is needed, which the FDC does not allow. Switch to separate, individually-dosed components.
In Child-Pugh C: All triamterene formulations are avoided.

Concurrent Hepatotoxin Note:

The following commonly used hepatotoxic drugs in Indian practice require additional caution and more frequent LFT monitoring when combined with triamterene in patients with any degree of hepatic impairment:

Hepatotoxic Drug	Specific Concern
Rifampicin	Potent CYP inducer — may paradoxically increase triamterene metabolism but also competes for hepatic processing in impaired liver. LFT monitoring at least every 2 weeks during co-administration.
Isoniazid	Hepatotoxicity risk; combined with triamterene’s folate antagonism may worsen nutritional anaemia. Supplement folic acid.
Methotrexate	⛔ Dual folate antagonism — triamterene (weak DHFR inhibitor) + methotrexate (potent DHFR inhibitor) = additive risk of megaloblastic anaemia and pancytopenia. This is a pharmacodynamic interaction; see Drug Interactions (Part 4). If both drugs are essential, mandatory folic acid supplementation and frequent CBC monitoring.
Valproate	Hepatotoxicity concern; both drugs may worsen folate status. Monitor LFT and CBC.
Anti-retrovirals (NNRTIs, PIs)	Complex hepatic metabolic interactions. Monitor LFTs. Data specifically for triamterene co-administration is very limited — exercise general caution.
Paracetamol (chronic use)	In patients with hepatic impairment already taking triamterene, chronic paracetamol use (even at 2 g/day) adds hepatic burden. Advise minimal paracetamol use.

ℹ️ Triamterene itself is not significantly hepatotoxic — it does not directly cause drug-induced liver injury (DILI) at therapeutic doses. The concern is about its altered pharmacokinetics in pre-existing liver disease and additive folate depletion, not direct hepatotoxicity.

When No Formal Child-Pugh-Based Dosing Data Exists — Practical Guidance:

Formal Child-Pugh-classified dosing studies for triamterene in hepatic impairment have not been conducted. The guidance above is based on the following pharmacokinetic principles:

High hepatic extraction ratio → Bioavailability is significantly increased when hepatic function is reduced (analogous to other high-extraction drugs like propranolol, lidocaine, verapamil)
Active metabolite formation is dependent on hepatic hydroxylation and sulfation → Metabolite levels are unpredictable in liver disease
Protein binding is reduced in hypoalbuminemia (common in Child-Pugh B and C) → Higher free drug fraction → Enhanced effect
Concurrent medications in liver disease (diuretics, beta-blockers, lactulose, antibiotics) add complexity
Folate status is commonly compromised in liver disease → Triamterene’s folate antagonism becomes clinically relevant

Statement: “No formal hepatic dosing data available for triamterene. Clinical guidance above is based on pharmacokinetic principles (high hepatic extraction, folate antagonism) and expert clinical practice.”

CONTRAINDICATIONS

An absolute contraindication means the drug must NEVER be used in this situation — the risk always outweighs any possible benefit.

#	Contraindication	Clinical Rationale
1	⛔ Hyperkalemia (serum K⁺ ≥5.5 mEq/L)	Triamterene’s entire mechanism of action reduces potassium excretion. Initiating the drug in a patient already hyperkalemic risks life-threatening cardiac arrhythmias (peaked T waves → widened QRS → sine wave → ventricular fibrillation/asystole).
2	⛔ Severe renal impairment (eGFR <15 mL/min) or anuria	Triamterene requires functioning nephrons to exert its effect. In severe renal failure: (a) no diuretic efficacy, (b) drug and active metabolite accumulate systemically, © already-impaired potassium excretion is further compromised → severe hyperkalemia.
3	⛔ Concurrent use with another potassium-sparing diuretic (spironolactone, eplerenone, or amiloride)	No therapeutic rationale for combining two potassium-sparing agents. Additive and unpredictable potassium retention with unacceptable hyperkalemia risk. Case reports of fatal hyperkalemia exist from inadvertent dual potassium-sparing diuretic prescribing.
4	⛔ Concurrent potassium supplementation (oral KCl, IV potassium) — unless documented hypokalemia under specialist supervision with inpatient-level monitoring	Exogenous potassium + impaired potassium excretion → rapid, dangerous hyperkalemia. The only exception is carefully supervised correction of documented, severe thiazide/loop-induced hypokalemia where both potassium supplementation and triamterene may be temporarily co-administered under daily serum K⁺ monitoring.
5	⛔ Addison’s disease (primary adrenal insufficiency) or other causes of hypoaldosteronism	In aldosterone-deficient states, potassium excretion is already severely impaired. Adding triamterene (which blocks the aldosterone-independent component of potassium secretion via ENaC) creates a “double block” on potassium excretion → severe hyperkalemia. Also applies to hyporeninemic hypoaldosteronism (Type IV RTA, common in diabetic nephropathy).
6	⛔ Severe hepatic impairment (Child-Pugh C) or hepatic coma/pre-coma	Impaired hepatic metabolism leads to unpredictable drug accumulation. Electrolyte disturbances (hypokalemia or hyperkalemia, hyponatremia) may precipitate or worsen hepatic encephalopathy. See Hepatic Adjustment (Part 3) for detailed rationale.
7	⛔ Known hypersensitivity to triamterene or any excipient in the formulation	Risk of anaphylaxis or severe hypersensitivity reaction on re-exposure. True allergy to triamterene is rare.
8	⛔ Haemodialysis or peritoneal dialysis patients	No diuretic effect in anuric/oliguric patients. Poorly dialysable drug — accumulates between sessions. Intractable hyperkalemia risk.

Allergy Cross-Reactivity

Triamterene is a pteridine derivative — structurally related to folic acid (which contains a pteridine ring) but structurally distinct from all other common drug classes associated with cross-reactivity (beta-lactams, sulfonamides, NSAIDs, local anaesthetics, iodinated contrast).

True immunologic cross-reactivity between triamterene and other drug classes is not well-documented. However, the following theoretical and structural relationships are worth noting:

Related Drug/Class	Cross-Reactivity Risk	Nature	Clinical Action
Amiloride (pyrazine derivative)	Negligible	Different chemical structure (pyrazine vs pteridine) despite shared pharmacological target (ENaC). No documented immunologic cross-reactivity.	If triamterene allergy is documented, amiloride may be safely used. Confirm with allergist if the original reaction was severe (anaphylaxis).
Folic acid / Folinic acid	Negligible	Structural similarity (pteridine ring) is pharmacologically relevant (DHFR inhibition) but immunologically insignificant. No documented cross-allergy.	Folic acid supplementation can be safely given alongside triamterene. No concern.
Trimethoprim (diaminopyrimidine)	Negligible	Both are folate antagonists, but structurally distinct (pyrimidine vs pteridine). Share a pharmacodynamic interaction (additive DHFR inhibition + hyperkalemia) but NOT immunologic cross-reactivity.	The concern with trimethoprim co-administration is pharmacodynamic (hyperkalemia, folate depletion), not allergic. See Drug Interactions.
Methotrexate	Negligible	Both are folate antagonists. Methotrexate is a 4-amino-10-methylfolic acid derivative. No documented immunologic cross-reactivity with triamterene.	Pharmacodynamic interaction concern (additive folate antagonism), not allergic cross-reactivity.
Sulfonamide antibiotics	Negligible	No structural relationship. Triamterene is NOT a sulfonamide.	No cross-reactivity concern. Triamterene can be used in patients with sulfonamide allergy.

ℹ️ Practical clinical note: True allergic reactions to triamterene are extremely rare. Most reported “intolerances” are pharmacological adverse effects (GI upset, hyperkalemia) rather than immune-mediated hypersensitivity. If a patient reports “allergy” to triamterene, carefully distinguish between true allergy (rash, urticaria, angioedema, anaphylaxis) and adverse effects.

CAUTIONS

⚠️ High-Priority Cautions

#	Condition	Risk	Required Monitoring/Action
1	⚠️ Renal impairment (eGFR 30–60 mL/min)	Reduced drug clearance, metabolite accumulation, enhanced potassium-sparing effect, reduced diuretic efficacy. Risk of hyperkalemia is substantially increased.	Dose reduction mandatory (see Part 3). Serum K⁺ at baseline, 48 hours, then weekly for 2 weeks, then every 2 weeks for 1 month, then monthly. Serum creatinine/eGFR at each K⁺ check. Consider discontinuation if eGFR declines further.
2	⚠️ Concurrent ACE inhibitor or ARB therapy	Both ACE inhibitors/ARBs and triamterene independently reduce potassium excretion. Combination significantly amplifies hyperkalemia risk — especially in elderly, diabetic, or renally impaired patients. Common clinical scenario in Indian practice: elderly hypertensive patient on enalapril + triamterene-benzthiazide FDC.	Serum K⁺ at baseline, within 3–5 days of starting the combination, at 1 week, 2 weeks, monthly for 3 months, then every 3 months. Use the minimum effective triamterene dose (50 mg/day maximum). Alert the patient about symptoms of hyperkalemia (weakness, palpitations, numbness).
3	⚠️ Diabetes mellitus	Diabetic patients (especially Type 2 with nephropathy) frequently have hyporeninemic hypoaldosteronism (Type IV RTA) — baseline potassium excretory capacity is already impaired. Adding triamterene further impairs it. Additionally, hyperglycemia-driven transcellular potassium shifts can compound the problem. Diabetic patients on ACEi/ARB + triamterene represent the HIGHEST-risk group for hyperkalemia.	Serum K⁺ monitoring at baseline and frequently thereafter (as per renal impairment schedule). Assess for Type IV RTA (unexplained hyperkalemia with relatively mild renal impairment, metabolic acidosis). Avoid the triple combination of ACEi/ARB + triamterene + potassium supplement.
4	⚠️ Concurrent digoxin therapy	The purpose of adding triamterene may be to prevent hypokalemia (which enhances digoxin toxicity) — this is rational. However, if triamterene OVER-corrects potassium → hyperkalemia in the setting of digoxin → unpredictable and potentially fatal cardiac arrhythmias (both hypokalemia and hyperkalemia sensitise the heart to digoxin).	Narrow therapeutic window for potassium: target 4.0–5.0 mEq/L. Monitor K⁺ more frequently (weekly during initiation, monthly once stable). Digoxin level monitoring also recommended.
5	⚠️ Pre-existing folate deficiency or at-risk populations	Triamterene is a weak DHFR inhibitor. In patients with marginal folate stores — alcoholic liver disease, malnutrition (common in lower socioeconomic populations in India), pregnancy, chronic haemolytic anaemias, concurrent anti-folate drugs — this weak inhibition can precipitate frank megaloblastic anaemia.	CBC (MCV, reticulocyte count) at baseline and every 3 months. Serum folate level at baseline if deficiency suspected. Supplement with folic acid 5 mg/day if deficiency is present or high-risk.
6	⚠️ History of kidney stones (any type)	Triamterene and its metabolites have very low solubility in acidic urine. Triamterene crystals can form de novo or serve as a nidus for calcium oxalate stone formation. Prior stone formers have an inherently higher recurrence risk.	Urinalysis at baseline — look for crystalluria. Advise adequate fluid intake (≥2.5 L/day). Avoid concurrent urinary acidifying agents. Consider urinary pH measurement. If crystalluria develops, discontinue triamterene. Amiloride or spironolactone are preferred alternatives in stone formers.
7	⚠️ Concurrent NSAID use (especially indomethacin)	NSAIDs reduce renal prostaglandin synthesis → decreased renal blood flow → reduced GFR → reduced diuretic efficacy AND enhanced potassium retention. The “triple whammy” (NSAID + ACEi/ARB + triamterene) is a well-documented cause of AKI + hyperkalemia. Indomethacin specifically has pharmacokinetic interactions with triamterene (competition at OAT transporters, reduced triamterene clearance).	Avoid concurrent NSAIDs if possible. If short-term NSAID use is unavoidable, monitor serum K⁺ and creatinine within 3–5 days. Ensure adequate hydration. Prefer paracetamol for analgesia.
8	⚠️ Metabolic acidosis (non-anion gap / hyperchloremic)	Triamterene, like amiloride, reduces hydrogen ion secretion in the collecting duct (blocking the lumen-negative potential that drives H⁺ secretion). This can cause or worsen a non-anion gap (Type IV) metabolic acidosis. Pre-existing metabolic acidosis may be compounded.	Check serum bicarbonate at baseline and periodically. If bicarbonate is <20 mEq/L and declining, reassess the need for triamterene.

Standard Cautions

#	Condition	Notes
1	Gout or hyperuricemia	Triamterene may elevate serum uric acid (weak effect — less pronounced than thiazides). In the FDC, the thiazide component is the primary contributor to hyperuricemia. Monitor uric acid levels in patients with a history of gout. Consider allopurinol prophylaxis if uric acid rises significantly (>9 mg/dL).
2	Volume depletion / dehydration	Any diuretic can worsen dehydration. Particularly relevant in Indian summer months (April–June) and during gastrointestinal illness (diarrhoea/vomiting). Advise adequate fluid intake. Consider temporarily withholding during acute illness with volume loss (see Sick Day guidance in Patient Counselling, Part 5).
3	Concurrent use of salt substitutes containing potassium	Many Indian patients use “low-sodium” salt (e.g., Tata Salt Lite, Nutrela Low Sodium Salt) which contains potassium chloride as a sodium replacement. This is an occult source of potassium that, combined with triamterene’s potassium-sparing effect, can cause hyperkalemia. Often overlooked in counselling.
4	Photosensitivity	Triamterene is a photosensitising agent. Patients may develop exaggerated sunburn-like reactions. Advise sun protection — particularly relevant in India where UV exposure is high year-round.
5	Patients on low-sodium diets	Strict sodium restriction (common dietary advice in hypertension/CHF) combined with triamterene + thiazide may cause symptomatic hyponatremia. Monitor serum Na⁺.
6	Perioperative period	Triamterene’s potassium-sparing effect may interact unpredictably with perioperative potassium-containing IV fluids, surgical stress-mediated potassium shifts, and anaesthetic agents. Consider withholding triamterene 2–3 days before elective surgery. Inform the anaesthesiologist. Check K⁺ preoperatively.
7	Breastfed infants of treated mothers	See Lactation section below.

PREGNANCY

Parameter	Details
Risk category / Overall safety statement	⚠️ Avoid during pregnancy unless no safer alternative exists. Classified as former US-FDA Category C (animal studies have shown adverse effects; no adequate human studies). No well-controlled human studies of triamterene in pregnancy. The combination of folate antagonism, electrolyte disturbance potential, and lack of safety data makes this drug a poor choice during pregnancy.
Teratogenicity window	The primary teratogenic concern (folate antagonism → neural tube defects) is highest during organogenesis (weeks 3–8 post-conception / weeks 5–10 gestational age). However, the risk is theoretical and not confirmed by human epidemiological data due to limited exposure data. Folate antagonism can affect fetal development throughout pregnancy (cell proliferation is folate-dependent throughout gestation).
Trimester-specific risks	First trimester: Theoretical teratogenicity risk from DHFR inhibition — analogous to the concern with other folate antagonists (trimethoprim, methotrexate). Neural tube defects, cardiovascular malformations, and cleft palate are the theoretical concerns, though NOT confirmed for triamterene specifically. Second/Third trimester: Electrolyte disturbances (hyperkalemia, hyponatremia) may affect the fetus. Reduced placental blood flow (if maternal hypovolemia occurs) may impair fetal growth. Triamterene crosses the placenta — direct fetal electrolyte effects possible. Near term / Delivery: Neonatal electrolyte disturbances possible if the mother was taking triamterene close to delivery. Monitor neonatal serum K⁺ in the first 24–48 hours after delivery.
Preferred alternatives in Indian obstetric practice	For hypertension in pregnancy: Methyldopa (first-line, established safety), Labetalol (second-line), Nifedipine extended-release (second-line). For edema in pregnancy: Physiological edema does not require diuretic treatment. Pathological edema (pre-eclampsia) is managed by definitive obstetric interventions, not diuretics. Diuretics (including triamterene) are generally not recommended for edema of pregnancy — they may reduce plasma volume and compromise uteroplacental perfusion. If a diuretic is absolutely necessary (e.g., pre-existing heart failure in pregnancy), furosemide under specialist supervision is preferred. No potassium-sparing diuretic has established safety in pregnancy.
When it may be used	Consider ONLY if: (a) The mother has a condition specifically requiring ENaC blockade (e.g., genetically confirmed Liddle syndrome presenting during pregnancy — extremely rare); (b) No safer alternative exists; © The benefit clearly outweighs the risk; (d) High-dose folic acid supplementation (5 mg/day) is given concurrently; (e) Specialist obstetrician + nephrologist/cardiologist oversight.
What to monitor (mother)	Serum K⁺, Na⁺, creatinine, CBC (for megaloblastic changes) — monthly. Blood pressure and volume status.
What to monitor (fetus)	Serial ultrasound for fetal growth. Fetal echocardiography if exposure during organogenesis (theoretical cardiac malformation risk from folate antagonism).
Pre-conception counselling requirements	Women of childbearing potential on triamterene should be counselled to: (a) Use reliable contraception; (b) Plan pregnancies; © Inform the prescriber before conception; (d) Switch to a pregnancy-safe antihypertensive/diuretic regimen before conception if possible; (e) Start high-dose folic acid (5 mg/day) at least 3 months before planned conception and continue through the first trimester.

Pregnancy Prevention Programme / Registry:
No mandatory pregnancy prevention programme exists for triamterene (unlike isotretinoin or thalidomide). No pregnancy exposure registry specific to triamterene is available. Report any inadvertent exposure during pregnancy to the prescribing physician for risk assessment and to PvPI for pharmacovigilance.

Fertility Effects:
No known direct effect on male or female fertility at therapeutic doses. Triamterene does not have anti-androgenic, anti-estrogenic, or gonadotoxic properties. No washout period before planned conception is required — simply switch to a pregnancy-safe alternative.

LACTATION

Parameter	Details
Compatibility with breastfeeding	Use with caution. Limited data available. Triamterene is likely excreted into breast milk (based on its physicochemical properties — moderate lipophilicity, moderate molecular weight). The active metabolite (p-hydroxytriamterene sulfate) is also likely present in milk.
Expected drug levels in milk	Data limited. No published RID (relative infant dose) available for triamterene. Given its moderate protein binding (~55–67%) and moderate lipophilicity, some transfer to breast milk is expected, but the degree is uncertain.
Preferred alternatives	If a potassium-sparing diuretic is needed during lactation, spironolactone has more published data on breastfeeding compatibility (low levels in milk, no reported adverse effects in breastfed infants in published case series). Amiloride data is also limited but is generally considered compatible with breastfeeding at usual doses. For hypertension during lactation: methyldopa, labetalol, nifedipine, and enalapril (for non-neonatal period) are preferred first-line agents with established lactation safety data.
What to monitor in infant	Monitor the breastfed infant for: (a) Adequate weight gain and feeding; (b) Signs of electrolyte disturbance — unusual irritability, lethargy, poor feeding (non-specific signs of hyperkalemia or dehydration); © Theoretically, folate status — but unlikely to be clinically significant with short-term maternal use.
Timing advice	If the prescriber decides that triamterene use during lactation is necessary, take the dose immediately after a breastfeeding session and delay the next feeding as long as practically possible (3–4 hours) to minimise peak milk drug levels. This advice is based on general pharmacokinetic principles for drugs with a Tmax of 1.5–3 hours.
Effect on milk production	No documented effect on milk production (neither suppression nor enhancement). Diuretics in general may theoretically reduce milk volume by reducing maternal fluid volume — but this is only clinically significant with potent loop diuretics at high doses or in volume-depleted mothers. Triamterene at standard doses is unlikely to affect milk production. Adequate maternal hydration should be maintained.
Temporary incompatibility guidance	Not applicable — triamterene is typically used chronically, not as a single dose. If used for a short course that will be discontinued, no specific pump-and-discard period is needed; the drug will clear from milk within ~24 hours of the last dose (based on active metabolite half-life of 3–5 hours × 5 half-lives ≈ 15–25 hours).

ELDERLY

Definition: For this formulary, elderly is defined as ≥60 years, consistent with Indian Census and National Programme for Health Care of the Elderly (NPHCE) definitions.

Parameter	Details
Recommended starting dose	25 mg once daily (half of a 50 mg capsule/tablet, or half of the FDC tablet if using triamterene + benzthiazide/HCTZ). If using the FDC, start with 1 tablet daily — this provides triamterene 50 mg which is acceptable in fit elderly patients with normal renal function. In frail elderly or those with eGFR 45–60 mL/min, consider sourcing single-ingredient triamterene for 25 mg/day dosing.
Need for slower titration	✔ Titrate no more frequently than every 2 weeks (vs 1 week in younger adults). Check serum K⁺ before each dose increase.
Maximum dose in elderly	100 mg/day (vs 200–300 mg/day in younger adults). Many elderly patients achieve adequate potassium-sparing with 50 mg/day.

Extra Risks Specific to Elderly:

Risk	Details	Mitigation
Hyperkalemia	The most important risk. Age-related GFR decline (even with “normal” creatinine — sarcopenia masks reduced GFR), concurrent ACE inhibitor/ARB use (very common in elderly hypertension management in India), diabetes, and Type IV RTA all converge in the elderly to dramatically increase hyperkalemia risk.	MANDATORY serum K⁺ at baseline, 3–5 days, 1 week, 2 weeks, then monthly for 3 months, then every 3 months. Calculate eGFR (CKD-EPI) — do not rely on serum creatinine alone in elderly patients.
Postural (orthostatic) hypotension	Combination of triamterene’s natriuretic effect (modest) + the thiazide component of the FDC + age-related baroreflex impairment + concurrent antihypertensives → risk of symptomatic orthostatic drop → falls. Falls in elderly Indian patients carry high morbidity (hip fractures, head injuries).	Measure orthostatic BP at each visit (supine → standing at 1 and 3 minutes). Advise slow position changes. Review total antihypertensive burden. Hydration advice — especially during Indian summer months.
Falls	Related to orthostatic hypotension (above), but also to potential dizziness and volume depletion. Diuretics are consistently identified as fall-risk medications in elderly patients.	Screen for fall risk (get-up-and-go test, fall history). Consider deprescribing the diuretic if falls occur.
Hyponatremia	The thiazide component of the FDC is the primary culprit. Elderly patients are more susceptible to thiazide-induced hyponatremia due to reduced free water excretion capacity, concurrent SSRIs (very common in elderly — additive SIADH-like effect), and dietary factors. Triamterene itself has a minor secondary effect.	Serum Na⁺ at baseline, 1 week, 1 month, then every 3 months. Be alert for non-specific symptoms: confusion, lethargy, unsteadiness, nausea — these may be attributed to “ageing” but may be hyponatremia.
Renal function decline	Elderly patients may have a progressive decline in GFR that crosses the threshold for safe triamterene use (eGFR <30 mL/min) during long-term treatment. A drug that was safe at initiation may become dangerous months or years later.	Check eGFR at least every 6 months. Reassess the need for triamterene at each eGFR check. Discontinue if eGFR <30 mL/min.
Dehydration	Elderly patients have reduced thirst perception and are susceptible to dehydration during hot weather (Indian summer), intercurrent illness (fever, GI infections), and Ramadan/Navratri fasting. Diuretics compound this risk.	“Sick day rules” — counsel patient/caregiver to withhold triamterene (and the FDC) during acute illness with reduced fluid intake, vomiting, or diarrhoea. Resume once eating and drinking normally.
Polypharmacy interactions	Elderly Indian patients frequently take multiple medications — ACE inhibitors, ARBs, NSAIDs (often OTC), digoxin, metformin, anti-TB drugs — each of which has specific interactions with triamterene.	Medication review at each visit. Be especially vigilant for the “triple whammy” (NSAID + ACEi/ARB + triamterene).
Folate deficiency	Elderly patients, especially those with poor nutrition, chronic illness, or alcoholism, are at higher risk of folate deficiency. Triamterene’s weak DHFR inhibition may tip them into megaloblastic anaemia.	CBC at baseline and every 6 months. Serum folate if MCV rises or anaemia develops. Consider empirical folic acid supplementation (5 mg/day) in at-risk elderly patients.

Beers Criteria / STOPP-START Relevance:

Beers Criteria (2023): Triamterene specifically is listed as “Use with caution in adults aged ≥65 years” due to hyperkalemia risk, especially when combined with ACE inhibitors, ARBs, or potassium supplements. The recommendation is to avoid combined use of triamterene with ACEi/ARB in elderly patients if potassium monitoring cannot be ensured.
STOPP Criteria (v2): STOPP D5 — “Thiazide diuretic with current significant hypokalaemia, hyponatremia, hypercalcaemia, or history of gout.” STOPP D6 — “Loop diuretic for treatment of hypertension with concurrent urinary incontinence.” While these primarily target the thiazide/loop component, they are relevant to the FDC. STOPP B10 — “Aldosterone antagonists (spironolactone, eplerenone) with concurrent potassium-conserving drugs without monitoring of serum potassium” — analogous caution applies to triamterene.
START Criteria: No START recommendation specifically endorses triamterene initiation in any elderly condition. Spironolactone is START-recommended in HFrEF.

ℹ️ These international criteria serve as additional reference — they are NOT primary Indian guidance but align with the general principle of caution with potassium-sparing agents in elderly patients.

Anticholinergic Burden:

No anticholinergic burden. Triamterene has no known anticholinergic receptor binding activity. It does not contribute to cumulative anticholinergic burden when combined with other medications. This is an advantage over some other drugs commonly used in elderly hypertensive patients (e.g., certain antihistamines, TCAs used as adjuncts).

Deprescribing Guidance:

Triamterene is a drug commonly considered for deprescribing in elderly patients. Consider deprescribing in the following scenarios:

Scenario	Action
Serum K⁺ is consistently ≥5.0 mEq/L	Stop triamterene. No taper needed — can be discontinued abruptly. Recheck K⁺ in 3–5 days after stopping.
eGFR has declined to <30 mL/min	Stop triamterene. Switch to alternative potassium management strategy if still needed (dietary advice, reduce concurrent potassium-wasting diuretic dose).
The original indication no longer applies (e.g., thiazide-induced hypokalemia resolved because the thiazide was stopped or dose reduced)	Stop triamterene. No taper needed.
Patient is on ACEi/ARB + triamterene and K⁺ is consistently 4.5–5.5 mEq/L	Consider stopping triamterene — the ACEi/ARB may be providing sufficient potassium-sparing effect.
Patient is on a “legacy” FDC prescription (triamterene + benzthiazide) that was started years ago without clear re-evaluation	Reassess: (a) Is the patient still hypertensive? (b) Is the benzthiazide still needed? © Is potassium-sparing still needed? Consider switching to a modern, evidence-based antihypertensive regimen (amlodipine, ACEi/ARB, chlorthalidone/indapamide).
Fall risk assessment is positive	Consider stopping or reducing the FDC diuretic (reducing volume depletion and orthostatic hypotension may reduce fall risk).

Tapering schedule: Not required. Triamterene can be stopped abruptly without withdrawal effects or rebound. However, if the patient was taking it for potassium-sparing alongside a thiazide, check serum K⁺ within 3–5 days of stopping to ensure hypokalemia does not recur.

Expected effects after stopping: Serum K⁺ may decline by 0.3–0.5 mEq/L within 3–7 days. Mild increase in sodium excretion may occur but is clinically insignificant. No rebound hypertension.

MAJOR DRUG INTERACTIONS

An interaction qualifies as MAJOR if it is contraindicated, can cause a life-threatening event, causes ≥2-fold change in AUC/Cmax, or requires mandatory dose adjustment or alternative drug selection.

#	Interacting Drug/Substance	Mechanism	Clinical Effect	Onset Type	Action Required
1	⛔ ACE Inhibitors (enalapril, ramipril, lisinopril, etc.)	Both reduce potassium excretion: ACEi reduces aldosterone → decreased K⁺ secretion; triamterene blocks ENaC → decreased K⁺ secretion. Additive, potentially synergistic potassium retention.	Severe hyperkalemia — risk is highest in elderly, diabetic, and renally impaired patients. ECG changes, cardiac arrhythmias, cardiac arrest. Published case series of fatal outcomes.	Gradual onset (days to weeks — K⁺ rises insidiously)	Avoid unless there is a clear clinical rationale and potassium can be monitored frequently. If combined: (a) Use minimum triamterene dose (50 mg/day maximum); (b) Monitor K⁺ at 3 days, 1 week, 2 weeks, monthly for 3 months, then every 3 months; © Target K⁺ 4.0–5.0 mEq/L; (d) Discontinue triamterene immediately if K⁺ ≥5.5 mEq/L.
2	⛔ ARBs (losartan, telmisartan, valsartan, olmesartan, etc.)	Same mechanism as ACE inhibitors — ARBs reduce aldosterone secretion.	Severe hyperkalemia — identical risk profile to ACEi combination.	Gradual onset	Same action as ACE inhibitors (above). Identical precautions.
3	⛔ Potassium supplements (oral KCl, IV potassium, potassium effervescent tablets)	Exogenous potassium load + impaired renal potassium excretion = rapid hyperkalemia.	Life-threatening hyperkalemia — can develop within hours of IV potassium or within 1–2 days of oral supplementation.	Acute onset (hours for IV KCl; 1–2 days for oral)	⛔ Do not co-prescribe unless documented hypokalemia under inpatient monitoring. If both are necessary, monitor K⁺ at least daily. Discontinue supplement as soon as K⁺ ≥4.5 mEq/L.
4	⛔ Other potassium-sparing diuretics (spironolactone, eplerenone, amiloride)	Additive potassium-sparing via complementary mechanisms (ENaC block + MRA or dual ENaC block).	Severe hyperkalemia. No therapeutic benefit from combination — only increased toxicity.	Gradual onset	⛔ Contraindicated. Never combine two potassium-sparing diuretics.
5	⚠️ Indomethacin	Dual interaction: (a) Pharmacokinetic — indomethacin competes with triamterene’s active metabolite at OAT1/OAT3 transporters → reduced metabolite renal clearance → metabolite accumulation; (b) Pharmacodynamic — indomethacin reduces renal prostaglandin synthesis → decreased GFR → reduced diuretic efficacy + enhanced potassium retention; © Nephrotoxic — combination has been associated with acute kidney injury in published case reports (including in Indian patients).	AKI + Hyperkalemia. May also worsen hypertension (NSAIDs oppose antihypertensive effects). Rapidly progressive renal deterioration has been reported.	Acute onset (within days)	⛔ Avoid this specific combination. If an NSAID is absolutely necessary, choose one with less COX-1 inhibition (e.g., celecoxib) for the shortest duration, with serum creatinine and K⁺ monitoring within 48–72 hours. Ensure adequate hydration.
6	⚠️ Other NSAIDs (ibuprofen, diclofenac, naproxen, piroxicam, etc.)	Same pharmacodynamic mechanism as indomethacin — though the pharmacokinetic OAT competition may be less pronounced than with indomethacin. NSAIDs reduce renal prostaglandin → reduced GFR → impaired potassium excretion + reduced diuretic efficacy. “Triple whammy” risk: NSAID + ACEi/ARB + triamterene.	AKI, hyperkalemia, worsened hypertension. Risk is lower than with indomethacin but still clinically significant, especially in the “triple whammy” scenario.	Acute to gradual onset (days)	Avoid if possible. If short-term NSAID use is unavoidable (<5 days), monitor creatinine and K⁺. Ensure hydration. Prefer paracetamol for analgesia. Never use the triple combination (NSAID + ACEi/ARB + triamterene) — documented cause of hospitalisation for AKI in Indian elderly patients.
7	⚠️ Trimethoprim (including co-trimoxazole/TMP-SMX)	Dual interaction: (a) Trimethoprim blocks ENaC in the collecting duct (same target as triamterene) — additive potassium-sparing; (b) Trimethoprim is a DHFR inhibitor (more potent than triamterene) — additive folate antagonism → megaloblastic anaemia risk.	Hyperkalemia (additive ENaC blockade) + Megaloblastic anaemia (additive folate antagonism). Case reports of severe pancytopenia with this combination.	Gradual onset (days to 1–2 weeks for hyperkalemia; weeks to months for megaloblastic changes)	Avoid unless clinical urgency for TMP-SMX and no alternative antibiotic. If combined: check K⁺ at 3 days and 1 week; supplement folic acid; monitor CBC. Duration should be as short as possible.
8	⚠️ Methotrexate	Additive folate antagonism: Methotrexate is a potent DHFR inhibitor; triamterene is a weak one. Combined DHFR inhibition → severe megaloblastic anaemia, pancytopenia, mucositis. Additionally, both drugs are organic anions cleared via OAT transporters — potential pharmacokinetic competition reducing methotrexate clearance → methotrexate toxicity.	Pancytopenia, severe megaloblastic anaemia, methotrexate toxicity. Potentially fatal bone marrow suppression.	Gradual onset (1–4 weeks)	⛔ Avoid this combination. If both drugs are essential (rare scenario), mandatory folic acid/folinic acid supplementation, frequent CBC (weekly for first month), and close monitoring for methotrexate toxicity. Consider amiloride or spironolactone as alternatives to triamterene.
9	⚠️ Lithium	Triamterene (like other diuretics) can reduce renal lithium clearance → lithium accumulation → toxicity. Mechanism: diuretic-induced volume contraction → enhanced proximal tubular sodium (and lithium) reabsorption. Additionally, triamterene’s ENaC blockade may alter distal lithium handling (lithium enters principal cells partly via ENaC).	Lithium toxicity — tremor, ataxia, confusion, seizures, renal failure. Risk amplified if patient also becomes dehydrated (common in Indian summer).	Gradual onset (days to 1–2 weeks)	Avoid if possible. If the combination is necessary, reduce lithium dose prophylactically, monitor lithium levels within 5–7 days of starting triamterene and after any dose change, and at least monthly during stable co-administration. Target lithium trough 0.6–0.8 mEq/L (lower end of therapeutic range).
10	⚠️ Cyclosporine	Cyclosporine causes hyperkalemia via multiple mechanisms (reduced renal K⁺ excretion, suppressed aldosterone). Triamterene adds further potassium retention.	Severe hyperkalemia. Risk is compounded by cyclosporine’s nephrotoxicity.	Gradual onset	⛔ Avoid this combination. If unavoidable (e.g., transplant patient with refractory hypokalemia from concurrent thiazide — very unusual), monitor K⁺ at least twice weekly. Specialist supervision mandatory.
11	⚠️ Tacrolimus	Same mechanism as cyclosporine — tacrolimus causes hyperkalemia through reduced renal K⁺ excretion.	Severe hyperkalemia.	Gradual onset	⛔ Avoid this combination. Same precautions as cyclosporine.
12	⚠️ Drospirenone (component of certain oral contraceptives, e.g., Yasmin)	Drospirenone has anti-mineralocorticoid activity (related to spironolactone) → potassium-sparing effect. Combined with triamterene → additive potassium retention.	Hyperkalemia.	Gradual onset (days to weeks)	Avoid if possible. If combined, monitor K⁺ within 1 week and monthly. Consider alternative OCP without drospirenone.

Food-Drug and Herb-Drug Interactions (Major)

Interacting Substance	Mechanism	Clinical Effect	Onset Type	Action Required
Potassium-rich foods (in EXCESS) — bananas, oranges, coconut water, dried fruits (dates, raisins, figs), tomatoes, potatoes, spinach, tender coconut, dal water	Dietary potassium load + impaired renal excretion → potassium accumulation	Hyperkalemia if excessive dietary potassium intake. Normal, balanced dietary potassium intake is fine — the concern is excessive or supplemental intake.	Gradual onset	Counsel patient to maintain a normal, balanced diet. Avoid excessive consumption of potassium-rich foods. Do NOT take potassium-enriched drinks/supplements. Monitor K⁺ regularly.
Potassium-containing salt substitutes (Tata Salt Lite, Nutrela Low Sodium Salt, “low-sodium” salts)	These contain KCl as a sodium replacement — significant potassium load. Patients may use them liberally without realising the potassium content.	Hyperkalemia — this is a frequently OVERLOOKED source of exogenous potassium in Indian households, especially in patients counselled to “reduce salt” for hypertension.	Gradual onset	⚠️ Actively ask about and counsel against the use of potassium-containing salt substitutes. This is one of the most common occult causes of hyperkalemia in Indian patients on potassium-sparing diuretics.
Traditional medicine interaction: Ashwagandha (Withania somnifera)	Ashwagandha has diuretic properties and may affect electrolyte balance. Mechanism not fully characterised.	Potential additive effect on electrolyte disturbance (hyperkalemia or hyponatremia). Clinical significance uncertain — but commonly used in Indian Ayurvedic/home practice.	Data limited	Counsel patients to inform the prescriber about any traditional medicine/supplement use. Monitor electrolytes if concurrent use is disclosed.
Traditional medicine interaction: Coconut water (Nariyal pani) — consumed as health drink	Very high potassium content (~250 mg per 240 mL). Often consumed daily in southern and coastal India as a “health drink” or “cooling agent.”	Hyperkalemia with regular, high-volume consumption alongside triamterene.	Gradual onset	Counsel to limit coconut water to 1 small glass (200 mL) per day maximum. Monitor K⁺ if regular consumption.

MODERATE DRUG INTERACTIONS

Interactions that usually can be managed with monitoring or minor dose adjustment.

#	Interacting Drug/Substance	Mechanism	Clinical Effect	Action Required
1	Digoxin	Triamterene is often ADDED to counteract thiazide/loop-induced hypokalemia in patients on digoxin (rational use). However, if triamterene over-corrects K⁺ → hyperkalemia in the setting of digoxin → increased risk of cardiac arrhythmias. Additionally, triamterene may mildly reduce renal clearance of digoxin (limited data).	Risk of both hyperkalemia and digoxin toxicity if K⁺ fluctuates outside the target range (4.0–5.0 mEq/L).	Monitor K⁺ closely (target 4.0–5.0 mEq/L). Monitor digoxin levels periodically (target 0.5–0.9 ng/mL for heart failure). Report any symptoms of digoxin toxicity (nausea, visual disturbances, bradycardia).
2	Other antihypertensives (amlodipine, beta-blockers, other diuretics, alpha-blockers, centrally-acting agents)	Additive BP-lowering effects.	Excessive hypotension, especially orthostatic hypotension. Risk highest in elderly and volume-depleted patients.	Monitor BP (including orthostatic) when adding or titrating triamterene alongside other antihypertensives. Reduce doses if symptomatic hypotension occurs.
3	Metformin	Both triamterene and metformin are organic cations/anions handled by renal tubular transporters. Triamterene’s metabolite competes at OAT1/3; metformin is handled by OCT2 and MATE1/2. Potential for pharmacokinetic interaction reducing metformin clearance — though clinical significance is uncertain.	Theoretical risk of metformin accumulation → lactic acidosis. Clinical significance is uncertain but case reports exist.	Monitor renal function. If eGFR declines to <45 mL/min in a patient on both drugs, the risk of metformin accumulation increases — consider dose reduction of metformin per standard guidelines.
4	Amantadine	Triamterene may reduce renal clearance of amantadine (competition at renal tubular transporters — both are organic cations).	Amantadine toxicity — confusion, hallucinations, myoclonus, seizures.	Monitor for amantadine CNS side effects. Consider dose reduction of amantadine by 25–50% if combined. Particularly relevant in elderly Parkinson’s patients who may be on both drugs.
5	Angiotensin receptor-neprilysin inhibitor (ARNI — sacubitril/valsartan)	ARB component (valsartan) reduces aldosterone → hyperkalemia risk (same as ARB alone, listed under Major interactions). Listed here additionally because the sacubitril component may further alter renal handling.	Hyperkalemia risk similar to ARB + triamterene.	Same precautions as ARB Major interaction. If ARNI is being used, triamterene addition requires careful justification and intensive K⁺ monitoring. Reduce triamterene to 50 mg/day maximum.
6	Heparin / Low-molecular-weight heparin (LMWH)	Heparin and LMWH can cause hyperkalemia by suppressing aldosterone synthesis (heparin-induced hypoaldosteronism).	Additive hyperkalemia risk when combined with triamterene. Often overlooked in hospitalised patients.	Monitor K⁺ at baseline and every 48–72 hours during concurrent use (common in hospitalised patients receiving DVT prophylaxis).
7	Sulfonylureas (glimepiride, glipizide, gliclazide)	Triamterene may impair glucose tolerance (weak effect — primarily the thiazide component of FDC). May alter sulfonylurea efficacy assessment.	Modest worsening of glycemic control in diabetic patients.	Monitor blood glucose/HbA1c during initiation and dose changes. Adjust sulfonylurea dose if needed.
8	Probenecid	Probenecid blocks OAT1/3 transporters → reduced renal secretion of triamterene’s active metabolite → metabolite accumulation → enhanced potassium-sparing effect.	Enhanced hyperkalemia risk. Reduced uricosuric effect of probenecid (triamterene may increase uric acid).	Monitor K⁺ if co-administered. Assess uric acid levels.
9	Folic acid supplements	Triamterene is a weak DHFR inhibitor — folic acid supplementation may be partially antagonised. However, at therapeutic folate supplement doses (5 mg/day), this antagonism is clinically overwhelmed.	No significant clinical problem — folic acid supplementation is recommended in at-risk patients on triamterene. The interaction is pharmacodynamic but of low clinical magnitude at supplemental folate doses.	No dose adjustment of folic acid needed. Standard supplementation doses (5 mg/day) are adequate to overcome triamterene’s weak DHFR inhibition.
10	Phenytoin / Carbamazepine (enzyme inducers)	Phenytoin and carbamazepine are CYP inducers, but triamterene’s metabolism does not primarily involve CYP enzymes. However, phenytoin is also a folate antagonist — additive folate depletion with triamterene.	Risk of megaloblastic anaemia from combined folate antagonism. No significant pharmacokinetic interaction.	Supplement folic acid. Monitor CBC for megaloblastic changes.

COMMON ADVERSE EFFECTS

Adverse effects occurring at ≥1% incidence, grouped by system.

Metabolic / Electrolyte

Adverse Effect	Frequency Band	Notes
Hyperkalemia (serum K⁺ >5.5 mEq/L)	Common (1–10%) — frequency highly variable depending on risk factors	Dose-dependent. Risk increases steeply with: higher doses (>100 mg/day), renal impairment, concurrent ACEi/ARB, diabetes, elderly age. May be asymptomatic initially — detected only on lab testing. Threshold for clinical significance: typically becomes symptomatic at K⁺ >6.0 mEq/L (muscle weakness, paraesthesias, ECG changes).
Hyponatremia (primarily with FDC — thiazide component)	Common (1–10%)	The thiazide component is primarily responsible. Triamterene contributes minimally. Elderly women are at highest risk. May present insidiously as confusion, lethargy, falls.
Elevated BUN / Serum creatinine	Common (1–10%)	Usually mild, prerenal (volume depletion–related). May also reflect reduced GFR from pharmacodynamic effect. Reversible with dose reduction or hydration.
Hyperuricemia	Common (1–10%)	Triamterene has a modest uricosuric-retaining effect; the thiazide component of the FDC is a stronger contributor. Rarely precipitates clinical gout unless the patient has pre-existing hyperuricemia. Dose-dependent — more common at >200 mg/day.
Metabolic acidosis (non-anion gap, hyperchloremic)	Common (1–10%)	Type IV RTA pattern. Results from reduced H⁺ secretion in the collecting duct (reduced lumen-negative potential due to ENaC blockade). Usually mild and asymptomatic. More pronounced in patients with pre-existing renal impairment or diabetes.

Gastrointestinal

Adverse Effect	Frequency Band	Notes
Nausea	Common (1–10%)	Usually transient. Mitigated by taking with food (which also improves bioavailability).
Diarrhoea	Common (1–10%)	Mild; dose-dependent.
Dry mouth	Common (1–10%)	Mild. Related to natriuretic/diuretic effect.
Epigastric discomfort / Dyspepsia	Common (1–10%)	Reduced by taking after meals.

Renal / Urinary

Adverse Effect	Frequency Band	Notes
Crystalluria	Common (1–10%)	Triamterene and metabolites are poorly soluble in acidic urine. Crystals may be found on routine urinalysis. Usually asymptomatic but can progress to nephrolithiasis (see Serious ADRs). Risk factors: concentrated urine, acidic urine pH, inadequate fluid intake. More common in Indian summer months.
Blue-green fluorescence of urine	Very common (≥10%)	Triamterene and its metabolites fluoresce under UV light and can impart a pale blue-green colour to urine. This is a benign pharmacological effect, NOT haematuria or pathology. Counsel patients that urine may appear slightly unusual in colour.

Central Nervous System

Adverse Effect	Frequency Band	Notes
Dizziness / Light-headedness	Common (1–10%)	Related to volume depletion and/or orthostatic hypotension. More common in elderly and during hot weather. Usually transient.
Headache	Common (1–10%)	Usually mild and transient.
Fatigue / Weakness	Common (1–10%)	May be related to electrolyte disturbance (check K⁺, Na⁺, Mg²⁺) or volume depletion.

Dermatological

Adverse Effect	Frequency Band	Notes
Photosensitivity	Common (1–10%)	Exaggerated sunburn reaction on UV-exposed skin. Triamterene absorbs UV light and may generate phototoxic metabolites. More clinically relevant in India (high ambient UV year-round). Counsel sun protection. Dose-dependent.

SERIOUS ADVERSE EFFECTS

Rare but clinically important adverse effects requiring immediate clinical attention.

⚠️ Signature ADR: Triamterene Nephrolithiasis / Crystalluria

⚠️ Triamterene-Specific — Signature ADR

This adverse effect is unique to triamterene within the potassium-sparing diuretic class. Neither amiloride nor spironolactone causes crystalluria or nephrolithiasis.

Parameter	Details
Incidence	Rare (<1%) for symptomatic nephrolithiasis; crystalluria (asymptomatic) is more common (1–10%). Exact incidence in Indian populations unknown — likely underreported.
Timing	Can occur at any time during therapy. Risk accumulates with prolonged use. Crystalluria may be detected within weeks of starting the drug; symptomatic stones typically develop after months to years of use.
Mechanism	Triamterene and its metabolite (p-hydroxytriamterene sulfate) have very low aqueous solubility, particularly in acidic urine (pH <5.5). As these compounds are concentrated in the renal tubular fluid and final urine, they may precipitate as triamterene crystals. These crystals can either form pure triamterene stones or act as a nidus for calcium oxalate deposition (mixed stones). Stone analysis in reported cases shows triamterene cores surrounded by calcium oxalate — a characteristic pattern.
Risk factors	(a) Concentrated urine (inadequate fluid intake, hot climate — particularly relevant in Indian context); (b) Acidic urine pH (<5.5); © Higher triamterene doses (>100 mg/day); (d) Prolonged use; (e) Pre-existing kidney stone history; (f) Concurrent use of urinary acidifying agents (ammonium chloride, methionine, ascorbic acid in large doses); (g) Dehydration from any cause
Detailed management protocol	If crystalluria detected (asymptomatic): (1) Increase fluid intake to achieve urine output ≥2.5 L/day; (2) Consider urine alkalinisation (potassium citrate — though this adds potassium load; sodium bicarbonate may be used cautiously); (3) If crystalluria persists despite hydration, discontinue triamterene and switch to amiloride or spironolactone; (4) Repeat urinalysis in 2–4 weeks. If symptomatic nephrolithiasis (renal colic): (1) Discontinue triamterene immediately — it is the causative agent; (2) Standard renal colic management — IV fluids, analgesia (diclofenac 75 mg IM stat — but note NSAID caution if patient has renal impairment; paracetamol IV 1 g as alternative), antispasmodic (hyoscine 20 mg IV); (3) Imaging — NCCT KUB to assess stone size and location; ℹ️ Triamterene stones are radiolucent on plain X-ray KUB (unlike calcium stones) — CT is the imaging modality of choice; (4) Urology referral if stone >6 mm or obstruction; (5) Stone analysis (if passed or retrieved) — send for infrared spectroscopy to confirm triamterene composition; (6) Never re-challenge with triamterene after confirmed triamterene nephrolithiasis.
Recurrence / Re-challenge policy	⛔ Do not re-challenge if triamterene nephrolithiasis is confirmed by stone analysis. For isolated, asymptomatic crystalluria that resolved with hydration and lower doses: re-challenge MAY be considered at a lower dose with rigorous hydration and periodic urinalysis — but this is rarely justified when alternatives (amiloride, spironolactone) exist.
Cross-reactivity implications	Amiloride does NOT cause crystalluria or nephrolithiasis — it is the preferred ENaC inhibitor in patients with stone history. Spironolactone also does not cause stones. Hydrochlorothiazide (often co-prescribed as FDC) actually reduces urinary calcium excretion and is used in hypercalciuric stone prevention — an interesting contrast to its combination partner triamterene which CAUSES stones.

ℹ️ Indian climate relevance: India’s hot climate, particularly during April–June in northern and central India, leads to increased insensible fluid losses and concentrated urine. This significantly amplifies triamterene crystalluria risk. Prescribers should proactively counsel patients to maintain high fluid intake (≥3 L/day) during hot months.

⚠️ Report any cases of triamterene nephrolithiasis to the nearest ADR Monitoring Centre under PvPI (Pharmacovigilance Programme of India) or via the ADR reporting form on the CDSCO website.

Other Serious Adverse Effects

#	Adverse Effect	Approx. Frequency	Details	Action
1	⚠️ Severe / Life-threatening hyperkalemia (K⁺ >6.5 mEq/L)	Rare to uncommon (depends on risk factors — may reach 1–5% in high-risk populations: elderly + renal impairment + ACEi/ARB)	ECG changes: peaked T waves (K⁺ 5.5–6.5), widened QRS (K⁺ 6.5–7.5), sine wave pattern (K⁺ >7.5), cardiac arrest (VF/asystole). May present insidiously — muscle weakness, paraesthesias, nausea, palpitations — or as sudden cardiac arrest.	Emergency management: (1) Stop triamterene immediately; (2) Calcium gluconate 10% — 10 mL (1 ampoule) IV over 2–3 minutes for cardiac membrane stabilisation (does NOT lower K⁺ — temporising measure); (3) Insulin 10 units regular IV + Dextrose 25% 50 mL IV to shift K⁺ intracellularly; (4) Salbutamol nebulisation 10–20 mg (shifts K⁺ intracellularly); (5) Sodium polystyrene sulfonate (Kayexalate) 15–30 g orally or rectally for potassium removal; (6) Haemodialysis if refractory or K⁺ >7.0 mEq/L with ECG changes; (7) Continuous cardiac monitoring. Specific antidote: No specific antidote for triamterene exists. Management is directed at correcting hyperkalemia. Calcium gluconate 10% injection is widely available in India.
2	⚠️ Megaloblastic anaemia	Rare (<1%)	Due to triamterene’s weak DHFR inhibitory activity → impaired folate metabolism → megaloblastic changes in bone marrow. Presents as macrocytic anaemia (MCV >100 fL), fatigue, glossitis, pancytopenia in severe cases. Risk factors: pre-existing folate deficiency (malnutrition, alcoholism, pregnancy), concurrent anti-folate drugs (methotrexate, trimethoprim, phenytoin), prolonged therapy (>6 months), elderly.	(1) Check serum folate, vitamin B12, and reticulocyte count; (2) Start folic acid 5 mg/day orally; (3) Discontinue triamterene if severe pancytopenia; (4) CBC response expected within 1–2 weeks of folate supplementation; (5) Consider switching to amiloride or spironolactone (neither has DHFR inhibitory activity).
3	⚠️ Acute kidney injury (AKI)	Rare (<1%)	Mechanisms: (a) Prerenal — from excessive volume depletion (especially with concurrent thiazide/loop diuretic + dehydration); (b) Intrarenal — rare cases of acute interstitial nephritis (hypersensitivity-mediated); © Obstructive — from triamterene crystal deposition causing intratubular obstruction.	(1) Discontinue triamterene; (2) IV fluid resuscitation; (3) If interstitial nephritis suspected (eosinophilia, rash, eosinophiluria): consider renal biopsy; short course of corticosteroids may be needed; (4) Nephrology referral; (5) Monitor for recovery.
4	Severe photosensitivity reaction	Rare (<1%)	May progress beyond simple phototoxic dermatitis to severe bullous or blistering photosensitivity resembling phototoxic drug eruption. More common with higher doses and prolonged UV exposure.	Discontinue triamterene. Dermatology referral. Strict UV avoidance. Topical and systemic corticosteroids for severe reactions.
5	Blood dyscrasias (thrombocytopenia, granulocytopenia)	Very rare (<0.1%)	Idiosyncratic reaction. May present with easy bruising, petechiae, recurrent infections, or unexplained fever. Mechanism unclear — possibly immune-mediated or related to folate depletion.	Discontinue triamterene immediately. CBC with differential. Haematology referral if severe. Supportive care. Usually reversible on discontinuation.
6	Hyponatremia — severe (Na⁺ <120 mEq/L)	Rare	Primarily from the thiazide component of the FDC, but triamterene may contribute by altering collecting duct sodium handling. Severe hyponatremia can cause seizures, coma, and permanent neurological damage if corrected too rapidly (osmotic demyelination syndrome).	(1) Discontinue the FDC; (2) If symptomatic (seizures, severe confusion): hypertonic saline (3% NaCl) under ICU supervision with sodium correction not exceeding 8 mEq/L in 24 hours; (3) If asymptomatic: fluid restriction, slow correction; (4) Monitor Na⁺ frequently during correction; (5) Nephrology/ICU referral.

⚠️ PvPI Reporting: Report ALL serious adverse effects to the nearest ADR Monitoring Centre under PvPI (Pharmacovigilance Programme of India) or via the ADR reporting form on the CDSCO website (https://cdsco.gov.in). This includes hyperkalemia requiring hospitalisation, AKI, nephrolithiasis, severe blood dyscrasias, and any adverse event resulting in hospitalisation, disability, or death.

LABORATORY TEST INTERFERENCE

Test	Type of Interference	Clinical Implication	Alternative Test Method
Urine glucose (Benedict’s reagent / Clinitest — copper reduction method)	False-positive — triamterene’s metabolites are reducing agents that react with copper reagent	May lead to erroneous diagnosis of glycosuria in non-diabetic patients or incorrect assessment of glycemic control in diabetic patients. Particularly relevant in Indian PHC/CHC settings where copper reduction methods may still be used.	Use glucose oxidase method (Glucostix / Diastix dipstick or enzymatic assay) — triamterene does NOT interfere with this method.
Serum creatinine (Jaffé colorimetric method)	False elevation — triamterene and metabolites may produce chromogenic interference in the alkaline picrate (Jaffé) reaction	May lead to overestimation of serum creatinine → underestimation of eGFR → inappropriate dose adjustments or unnecessary drug cessation. The interference is modest (typically <0.2 mg/dL) but can be clinically significant in patients with borderline renal function. More relevant in Indian settings where Jaffé method is still the predominant creatinine assay.	Use enzymatic creatinine assay (creatinine amidohydrolase or creatininase method) — eliminates this interference. If enzymatic assay is not available, be aware that measured creatinine may be slightly higher than true value.
Urine fluorescence	Triamterene and metabolites are intensely fluorescent under UV light (blue-green)	May interfere with fluorometric assays for other drugs or metabolites performed on urine. May cause false-positive “fluorescence screening” results in certain toxicology screens. Importantly, it causes the urine to appear blue-green under normal light in some patients — this is benign but may alarm patients or laboratory staff.	Inform the laboratory that the patient is on triamterene. Use non-fluorometric assay methods where available.
Lactic dehydrogenase (LDH) — fluorometric assay	Assay interference — triamterene’s fluorescence interferes with fluorometric LDH determination	May give inaccurate LDH values — either falsely elevated or unreliable.	Use spectrophotometric LDH assay (non-fluorometric method).
Serum potassium (in hemolysed sample)	Not a drug-specific interference, but a critical practical note: hemolysed blood samples give falsely elevated K⁺ readings. This is especially common in Indian primary care settings (difficult venepuncture, delayed processing). In a patient on triamterene, a falsely elevated K⁺ may trigger unnecessary drug discontinuation or emergency interventions.	Inappropriately stopping triamterene based on a hemolysed sample → patient loses potassium-sparing benefit → hypokalemia recurrence. OR unnecessary emergency hyperkalemia management for a lab artefact.	Always confirm an unexpectedly elevated K⁺ in a clinically stable patient by repeating the sample with careful phlebotomy (21G or larger needle, avoid tourniquet time >1 minute, prompt processing, no shaking of sample). If ECG shows no hyperkalemic changes and the patient is asymptomatic, a repeat sample is warranted before clinical action.
Urine examination — crystal identification	Triamterene crystals may be misidentified as uric acid crystals by inexperienced microscopists	Misidentification may lead to incorrect diagnosis of hyperuricosuria/uric acid stone disease rather than recognition of triamterene crystalluria. Triamterene crystals are typically needle-shaped or fan-shaped and birefringent under polarised light, distinguishable from the rhomboid/rosette forms of uric acid.	Inform the laboratory that the patient is on triamterene. Request specific notation of crystal type. If stone analysis is performed, request infrared spectroscopy (not just visual/chemical analysis) — this definitively distinguishes triamterene from uric acid.

MONITORING REQUIREMENTS

Baseline (Before Starting)

Parameter	Grade	Details	Resource-Limited Setting Surrogate
Serum potassium	MANDATORY	Do NOT start triamterene without a baseline K⁺ result. If K⁺ ≥5.0 mEq/L, do not initiate. If K⁺ 4.5–5.0 mEq/L, exercise extreme caution and ensure close follow-up. Confirm a non-hemolysed sample.	If laboratory K⁺ is not available (remote PHC), do a baseline ECG — look for peaked T waves, prolonged PR, widened QRS. Also assess clinical risk: is the patient on ACEi/ARB? Is there known renal impairment? If high-risk features are present and K⁺ testing is not possible, do not start triamterene — refer to a facility with laboratory access.
Serum creatinine + eGFR calculation	MANDATORY	Calculate eGFR by CKD-EPI (adults) or Schwartz formula (paediatrics). Do not start if eGFR <30 mL/min. Use with extreme caution if eGFR 30–45 mL/min. Do not rely on serum creatinine alone in elderly patients — sarcopenia masks reduced GFR.	If eGFR cannot be calculated (no creatinine available), assess clinical risk: age >60, diabetes, known kidney disease, concurrent nephrotoxic drugs. If any present, defer triamterene initiation until creatinine/eGFR is available.
Serum sodium	RECOMMENDED	Particularly important if using the FDC (thiazide component causes hyponatremia). If Na⁺ <130 mEq/L, correct hyponatremia before starting the FDC.	Clinical assessment: confusion, lethargy, unsteadiness in an elderly patient may indicate pre-existing hyponatremia.
Serum magnesium	RECOMMENDED	Especially if patient is on concurrent digoxin (hypomagnesemia enhances digoxin toxicity) or loop diuretics (which cause magnesium wasting).	Not easily assessed clinically. If lab unavailable, consider empirical magnesium supplementation in patients on chronic loop diuretics + digoxin.
Blood urea nitrogen (BUN)	RECOMMENDED	Helps assess prerenal status and hydration. Elevated BUN:creatinine ratio (>20:1) suggests volume depletion — cautious diuretic use.	Clinical assessment of hydration status: skin turgor, mucous membranes, orthostatic vital signs.
Complete blood count (CBC) with MCV	RECOMMENDED	Baseline for monitoring megaloblastic changes (rising MCV). Particularly important in patients at risk of folate deficiency: elderly, malnourished, alcoholic, concurrent anti-folate drugs.	If CBC unavailable, assess clinically for pallor, glossitis (smooth red tongue), and angular stomatitis at each visit.
Serum uric acid	OPTIONAL but helpful	Baseline value helps interpret future changes. More relevant if patient has history of gout or hyperuricemia. The FDC (thiazide component) is the primary contributor to uric acid elevation.	Not essential if no gout history. Can be deferred if lab access is limited.
Urinalysis (including microscopy)	RECOMMENDED	Look for pre-existing crystalluria, proteinuria, and urinary pH. Baseline urinary pH helps assess crystalluria risk (pH <5.5 = higher risk).	Dipstick urinalysis is available in most settings and provides adequate baseline information.
Blood glucose (fasting)	RECOMMENDED	Primarily relevant if using the FDC (thiazide component may impair glucose tolerance).	Clinical assessment: polyuria, polydipsia, weight loss. Capillary glucose testing is widely available.
ECG	OPTIONAL but helpful	Baseline ECG to assess for pre-existing conduction abnormalities or signs of electrolyte disturbance. Particularly recommended in elderly, patients on digoxin, and those with cardiac disease.	If 12-lead ECG is unavailable, cardiac auscultation for rate and rhythm. Pulse rate monitoring.
Blood pressure (including orthostatic)	MANDATORY	Baseline seated and standing BP. Document orthostatic drop if present.	Available in all settings — sphygmomanometer is universal.

After Initiation / Dose Change

Timing	Parameters	Notes
3–5 days	Serum K⁺, serum creatinine	Critical early check — hyperkalemia risk is highest during the first 1–2 weeks. If K⁺ ≥5.5 mEq/L, reduce dose or discontinue. If creatinine rises >25%, reassess.
1 week	Serum K⁺, serum creatinine, serum Na⁺	Repeat electrolyte panel. Reassess BP response.
2 weeks	Serum K⁺, BP (including orthostatic)	If K⁺ remains 4.0–5.0 mEq/L and creatinine stable, continue at current dose.
1 month	Serum K⁺, creatinine, eGFR, Na⁺, BUN, BP	Comprehensive metabolic reassessment. If on concurrent ACEi/ARB: additional K⁺ check is prudent.
After any dose increase	Serum K⁺ at 3–5 days post-increase	Repeat the early monitoring cycle for each dose escalation.
After adding an interacting drug (ACEi, ARB, NSAID, TMP-SMX, etc.)	Serum K⁺ and creatinine at 3–5 days	Proactive monitoring for pharmacodynamic/pharmacokinetic interactions.

Long-Term / Maintenance Monitoring

Parameter	Frequency	Notes
Serum potassium	Every 3 months (stable patients); monthly if high-risk (elderly, renal impairment, concurrent ACEi/ARB, diabetes)	The most important single monitoring parameter. Hyperkalemia can develop insidiously even after months of stable K⁺.
Serum creatinine + eGFR	Every 6 months (stable patients); every 3 months if eGFR 30–60 mL/min	Tracks renal function trajectory. If eGFR declines below 30 mL/min during treatment, discontinue triamterene.
Serum sodium	Every 6 months if on FDC (thiazide component)	More frequently (every 3 months) in elderly, patients on SSRIs, or those with prior hyponatremia.
CBC with MCV	Every 6 months	Monitor for rising MCV (megaloblastic change from folate depletion). If MCV >100 fL, check serum folate and B12. Supplement folic acid if deficient.
Serum uric acid	Every 6–12 months if on FDC; only if symptomatic gout or baseline hyperuricemia	Low-priority unless clinically indicated.
Urinalysis	Every 6–12 months	Screen for crystalluria. If crystalluria detected, increase fluid intake and reassess drug necessity.
Blood glucose / HbA1c	Annually if on FDC (thiazide component); per diabetic management schedule if diabetic	Thiazide component may worsen glucose tolerance.
Blood pressure (including orthostatic in elderly)	Every visit (at least every 3 months)	Standard antihypertensive monitoring.
Serum magnesium	Annually; more frequently if on concurrent digoxin or loop diuretics	Often forgotten — low magnesium contributes to refractory hypokalemia and digoxin toxicity.

Therapeutic Drug Monitoring (TDM)

Not applicable. Triamterene does not require serum drug level monitoring. Dosing is guided by clinical response (BP, edema) and serum potassium (the pharmacodynamic endpoint), not by plasma drug concentrations.

When to Stop Monitoring

Monitoring for serum potassium, creatinine, and eGFR should continue for the entire duration of triamterene therapy. There is no point at which monitoring can be safely discontinued while the drug is being taken. The risk of hyperkalemia persists throughout treatment and may increase over time as renal function naturally declines with age.

After triamterene is discontinued: check serum K⁺ once at 3–5 days post-discontinuation to confirm no rebound hypokalemia (from loss of potassium-sparing effect while thiazide/loop diuretic continues). No further triamterene-specific monitoring is needed after that.

Common Investigation Misconception Flag

ℹ️ Serum potassium from a hemolysed sample is NOT a reliable indicator of true potassium status. This is the most common source of falsely elevated K⁺ readings in Indian practice. If an unexpectedly high K⁺ is reported in a clinically stable patient, repeat the sample with careful phlebotomy technique (see Laboratory Test Interference) before making clinical decisions.

ℹ️ Spot urine potassium is frequently ordered to assess potassium homeostasis but is unreliable without concurrent urine creatinine measurement. A urine potassium-to-creatinine ratio or 24-hour urine potassium excretion is more informative. In resource-limited settings, rely on serial serum potassium measurements.

PATIENT COUNSELLING

Written in simple language that a doctor can directly convey to the patient during consultation. This is a ready reference for the prescribing clinician to use during patient education.

What this medicine is for

“This medicine helps your body hold on to potassium — a mineral that your heart and muscles need. You are taking it along with another water pill (diuretic) that removes extra salt and water from your body but also removes potassium. This medicine protects your potassium levels.”

How to take it

“Take this medicine with food or right after a meal — it works much better when taken with food and is also less likely to upset your stomach.”
“Take it in the morning (or morning and early afternoon if taking it twice a day). Do not take it in the evening or at bedtime — it will make you pass more urine and disturb your sleep.”
“Swallow the capsule/tablet whole with a full glass of water. If you have trouble swallowing, you may open the capsule and mix the powder with a small amount of curd (dahi) or soft food — but the taste may be bitter.”
“Try to take it at the same time(s) every day.”

What to do if you miss a dose

“If you take it once a day: If you remember within 12 hours, take the missed dose with food. If more than 12 hours have passed, skip the missed dose and take the next one at your usual time.”
“If you take it twice a day: If you remember within 6 hours, take the missed dose with food. If more than 6 hours have passed, skip it and take the next dose at your usual time.”
“Never take a double dose to make up for a missed one.”
“If you miss your medicine for more than 3 days in a row, tell your doctor before restarting — a blood test may be needed.”

Common side effects to expect

“You may notice your urine looks slightly blue-green or different in colour — this is normal and harmless. It is caused by the medicine.”
“You may feel mild nausea, stomach discomfort, or loose motions when you first start. These usually improve within a few days. Taking the medicine with food helps.”
“You may feel slightly dizzy or light-headed, especially when standing up quickly from sitting or lying down. Stand up slowly.”
“Your skin may become more sensitive to sunlight — you may sunburn more easily. Wear a hat, use sunscreen, and avoid prolonged sun exposure.”

Warning signs to report immediately

⚠️ Tell your doctor immediately or go to a hospital if you notice any of the following:

“Unusual weakness, tiredness, or heavy feeling in your legs — this could be a sign that your potassium is too high.”
“Heart beating very fast, very slow, or in an uneven rhythm (palpitations) — this is a serious warning sign.”
“Numbness or tingling in your hands, feet, or around your mouth.”
“Passing very little urine, or no urine at all — this could mean a kidney problem.”
“Severe pain in your back or side, or blood in your urine — this could be a kidney stone.”
“Feeling very confused, extremely drowsy, or having difficulty speaking — especially in elderly patients, this could mean a sodium problem.”
“Easy bruising, unusual bleeding, or getting many infections — this is rare but could mean a blood problem.”

Things to avoid

“Do not use ‘low-sodium’ salt or ‘lite’ salt (like Tata Salt Lite or similar products). These contain potassium and can dangerously raise your potassium levels when combined with this medicine. Use regular salt in moderation, or as your doctor advises.”
“Do not take potassium supplements or potassium-containing tablets/syrups unless your doctor specifically tells you to.”
“Do not eat very large amounts of potassium-rich foods every day — such as bananas, oranges, coconut water, dried fruits (dates, raisins, figs), tomatoes, or spinach. A normal amount of these foods is fine. Do not avoid them completely — just do not eat them in excess.”
“Do not take pain-killers like ibuprofen, diclofenac, or Combiflam without asking your doctor first — these medicines can cause kidney problems and raise potassium when combined with your medicine. Paracetamol (Crocin/Dolo) is safer for pain relief.”
“Avoid excessive sun exposure — your skin is more sensitive while on this medicine. Use sunscreen (SPF 30+) and wear protective clothing, especially during 10 AM – 4 PM.”
“Limit alcohol — alcohol can increase dizziness and dehydration.”

Storage

“Keep the medicine in a cool, dry place, away from direct sunlight and moisture.”
“In hot summer months, store in the coolest part of your house — not in the kitchen or bathroom.”
“Do not refrigerate unless the packaging specifically says so.”
“Keep out of reach of children.”

Duration

“This medicine is usually taken for a long time — as long as you are also taking your water pill (diuretic). Do not stop it on your own without talking to your doctor.”
“You can stop this medicine abruptly if needed — it will not cause withdrawal effects. But tell your doctor, because your potassium levels may need to be rechecked.”

Follow-up

“You must get regular blood tests to check your potassium and kidney function. Your doctor will tell you how often.”
“In the beginning, blood tests may be needed every few days to 1 week. Once stable, every 3 months is usually enough.”
“Always bring your blood test results to every doctor visit.”
“Tell every doctor, dentist, or pharmacist you visit that you are taking this medicine.”

Common Patient Questions Addressed

Question	Response
“Can I take this with my other medicines?”	“In most cases, yes — but it is very important to tell your doctor about ALL medicines you take, including Ayurvedic medicines, supplements, and over-the-counter pain killers. Some combinations are dangerous.”
“Can I take this during fasting (Ramadan/Navratri/Ekadashi)?”	Fasting Period Guidance: Triamterene is usually taken once or twice daily. During fasting: If once-daily dosing: Take after the predawn meal (sehri) or after the evening meal (iftar/Navratri dinner). This is usually manageable. If twice-daily dosing: Take one dose after sehri/predawn meal and one after iftar/evening meal. The interval may be shorter than usual but is generally acceptable. Important: Fasting reduces fluid intake → concentrated urine → increased risk of kidney crystals/stones. Increase fluid intake during non-fasting hours (aim for ≥2.5 L between iftar and sehri, or between meals during Navratri). If you feel weak, dizzy, or unwell during fasting, break the fast and take your medicine — most religious authorities allow medical exemptions from fasting. Discuss with your religious advisor if unsure.
“Will this affect my ability to drive/work?”	“This medicine can cause mild dizziness, especially when you first start it or when the dose is increased. If you feel dizzy, do not drive or operate heavy machinery until the dizziness settles.”
“Is this medicine habit-forming?”	“No, this medicine is not habit-forming. You will not become dependent on it.”
“Can I stop once I feel better?”	“Do not stop without asking your doctor. High blood pressure and fluid retention often have no symptoms — you may feel fine but still need the medicine. Stopping it may cause your potassium to drop (if you are also on another diuretic).”
“Can I take this if I am pregnant or breastfeeding?”	“This medicine is generally not recommended during pregnancy — safer alternatives exist. If you are pregnant, planning to become pregnant, or breastfeeding, tell your doctor immediately so the medicine can be changed.”
“My urine looks greenish — is something wrong?”	“No, this is a normal effect of the medicine. It is not harmful. The medicine and its breakdown products cause a slight colour change in urine. This is expected and will stop when the medicine is stopped.”

Caregiver/Family Counselling

For elderly patients or those with cognitive impairment:

"Counsel the caregiver/family member on:

Making sure the medicine is taken with food, at the right time (morning/early afternoon)
Watching for signs of weakness, confusion, irregular heartbeat, or reduced urine output — and reporting these to the doctor
NOT giving ‘low-sodium’ salt substitutes in cooking — use regular salt in moderation
NOT giving over-the-counter pain killers (especially ibuprofen/diclofenac) without doctor’s advice
Ensuring adequate fluid intake, especially in summer
Reminding the patient about follow-up blood tests
If the patient falls: inform the doctor — the diuretic dose may need to be reduced
Keeping a medication diary to track doses and blood test dates"

India-Specific Adherence Support

Barrier	Guidance
Cost-driven non-adherence	“If cost is a concern, ask your doctor about generic alternatives or check availability at the nearest Jan Aushadhi Kendra (PMBJP store). The triamterene + benzthiazide FDC is relatively inexpensive.”
Polypharmacy burden	“If you are taking many medicines, ask your doctor to review which ones are essential. Do not stop any medicine on your own.”
Temperature-sensitive storage	“In Indian summer (April–June), store medicines in the coolest, driest room. Do not leave them in a car, near a window with direct sunlight, or in the kitchen near the stove.”
Rural access / Refill difficulty	“If you cannot get a refill on time, do not panic — missing 1–2 days will not cause immediate harm. But try to get your medicine as soon as possible and tell your doctor at the next visit if you had to miss doses. The doctor may need to recheck your blood tests.”
TDS dosing difficulty	Not applicable — triamterene is dosed once or twice daily, which is generally manageable.

BRANDS AVAILABLE IN INDIA

Jan Aushadhi / PMBJP Brands

ℹ️ No Jan Aushadhi (PMBJP) brand of triamterene (single-ingredient or FDC) is currently available as of the date of this monograph. The drug is not listed in the current PMBJP product catalogue.

Major Private Brands

Single-Ingredient Triamterene:

Brand Name	Manufacturer	Strength	Availability
—	—	—	⚠️ Very limited availability. Single-ingredient triamterene is not commonly stocked in Indian retail pharmacies. It may be available through hospital pharmacies, online pharmacy platforms (1mg, PharmEasy, Netmeds), or on special order. Prescribers should confirm availability before writing a prescription.

ℹ️ Single-ingredient triamterene brand availability is extremely limited in the Indian market. Most manufacturers have discontinued single-ingredient products in favour of the FDC.

FDC: Triamterene + Benzthiazide (50 mg + 25 mg):

Brand Name	Manufacturer	Dosage Form	Availability
Ditide	GlaxoSmithKline Pharmaceuticals (now Haleon/GSK)	Tablet	Widely available — historically one of the most recognised diuretic brands in India. Available in most retail pharmacies across metros, Tier-2, and Tier-3 cities.
Triteren	Select manufacturers	Tablet	Metro/urban availability
Triamterol	Select manufacturers	Tablet	Limited availability

ℹ️ Ditide (Triamterene 50 mg + Benzthiazide 25 mg) is by far the dominant brand in this category. It has been marketed in India for several decades and remains widely recognised among prescribers and patients.

FDC: Triamterene + Hydrochlorothiazide (50 mg + 25 mg):

Brand Name	Manufacturer	Dosage Form	Availability
Various manufacturers	—	Capsule/Tablet	Limited availability — less commonly prescribed in India compared to the triamterene + benzthiazide FDC. May be sourced through select pharmacies or online platforms.

CDSCO Regulatory Notes:

No Not of Standard Quality (NSQ) alerts or product recalls specific to triamterene brands have been identified in recent CDSCO notifications as of the date of this monograph. Prescribers should check the CDSCO website periodically for updated NSQ alerts.
No triamterene-containing FDC has been banned by CDSCO.

PRICE RANGE (INR)

Formulation	Strength	Pack Size	Approximate Price (INR)	Per-Unit Cost (INR)
Ditide tablet (Triamterene 50 mg + Benzthiazide 25 mg)	50 mg + 25 mg	10 tablets	₹15–25	₹1.50–2.50 per tablet
Ditide tablet	50 mg + 25 mg	100 tablets	₹100–150	₹1.00–1.50 per tablet
Single-ingredient triamterene (if available)	50 mg / 100 mg	10 capsules	Data limited — not routinely priced in Indian pharmacy databases due to very limited availability	—

NPPA Price Control Status:

Triamterene is NOT included in the current NLEM India (2022) and is therefore NOT under NPPA (National Pharmaceutical Pricing Authority) price control under the Drug Prices Control Order (DPCO). Manufacturers set prices based on market dynamics.

PMBJP Store Availability: Not available through PMBJP (Jan Aushadhi) stores.

Government Supply Price: Triamterene is not a commonly procured drug in government hospital supply chains. It is not listed in most state drug procurement lists. Government hospital formularies in India typically include spironolactone and furosemide as standard diuretics; triamterene is an uncommonly stocked item.

Per-Month Cost Estimate (at Usual Maintenance Dose)

Dose	Monthly Tablet Count	Estimated Monthly Cost (INR)
1 tablet/day of Ditide (50 mg + 25 mg) — most common regimen	30 tablets	₹45–75
2 tablets/day of Ditide (100 mg + 50 mg total daily) — maximum FDC dose	60 tablets	₹90–150

💡 Triamterene (as the Ditide FDC) is a low-cost medication — affordability is generally not a barrier to adherence.

Comparative Cost Context

Drug	Typical Monthly Cost (INR) at Usual Maintenance Dose	NLEM Status	Availability
Triamterene 50 mg + Benzthiazide 25 mg (Ditide) — 1 tab/day	₹45–75	Not in NLEM	Widely available
Spironolactone 25 mg — 1 tab/day	₹30–60	✔ In NLEM	Widely available
Spironolactone 50 mg — 1 tab/day	₹50–100	✔ In NLEM	Widely available
Amiloride 5 mg + HCTZ 50 mg (FDC) — 1 tab/day	₹30–70	Amiloride + HCTZ in NLEM	Metro/urban availability
Hydrochlorothiazide 12.5 mg — 1 tab/day (without potassium-sparing)	₹10–20	✔ In NLEM	Widely available
Chlorthalidone 12.5 mg — 1 tab/day	₹30–60	✔ In NLEM	Widely available
Eplerenone 25 mg — 1 tab/day	₹200–500	Not in NLEM	Metro/urban availability

ℹ️ Key takeaway: Triamterene (as Ditide FDC) is comparably priced to spironolactone and amiloride-HCTZ FDC. Eplerenone is substantially more expensive. Cost is NOT a differentiating factor between triamterene and spironolactone — the choice is driven by clinical factors (anti-androgenic effects, outcome data, crystalluria risk), not price.

Prices as of June 2025. Verify current prices on NPPA/1mg/PharmEasy/Jan Aushadhi price lists as prices may change.

CLINICAL PEARLS

💡 Pearl 1: The “Ditide Legacy” — Re-evaluate Old Prescriptions [Practice-based]

The Triamterene + Benzthiazide FDC (Ditide) was one of the most widely prescribed antihypertensives in India during the 1980s–2000s. Many elderly patients continue on this prescription from decades ago without re-evaluation. At every encounter with an elderly patient on Ditide, ask: (a) Is the blood pressure still above target — or is the patient now normotensive or hypotensive? (b) Is potassium-sparing still needed — or was it empirically added without documented hypokalemia? © Has renal function declined to a level where triamterene is unsafe? (d) Would a modern, evidence-based regimen (ACEi/ARB + amlodipine or chlorthalidone) be more appropriate? Many of these patients are candidates for deprescribing the FDC and switching to a regimen with cardiovascular outcome data.

💡 Pearl 2: Myth vs Fact — “All Potassium-Sparing Diuretics Are Interchangeable” [Evidence-based]

Myth: Triamterene, amiloride, and spironolactone are interchangeable because they all “spare potassium.”

Fact: These three drugs have fundamentally different mechanisms, clinical evidence bases, and adverse effect profiles:

Spironolactone blocks the mineralocorticoid receptor → addresses aldosterone-mediated pathology → has mortality data in HFrEF (RALES) and resistant hypertension (PATHWAY-2) → but causes gynecomastia, menstrual irregularity.
Amiloride blocks ENaC directly → aldosterone-independent → better PK predictability than triamterene → NO crystalluria risk → preferred ENaC inhibitor.
Triamterene blocks ENaC directly → similar to amiloride but with worse PK (variable bioavailability), weak DHFR inhibition (folate antagonism), and UNIQUE risk of crystalluria/nephrolithiasis.
Substituting one for another requires understanding these distinctions. Triamterene should NOT be substituted for spironolactone in HFrEF — there is no outcome equivalence.

💡 Pearl 3: The “Triple Whammy” — India’s Most Preventable Cause of AKI in the Elderly [Evidence-based]

The combination of NSAID + ACE inhibitor/ARB + diuretic (including triamterene) is a well-documented cause of acute kidney injury, particularly in elderly patients. In Indian clinical practice, this “triple whammy” is alarmingly common because: (a) NSAIDs (ibuprofen, diclofenac) are available OTC and widely self-medicated; (b) ACE inhibitors/ARBs are standard first-line antihypertensives; © Diuretic FDCs (like Ditide) are commonly co-prescribed. At every visit, actively ask elderly patients on triamterene-containing regimens whether they are taking any OTC pain killers. Counsel strongly against unsupervised NSAID use. Paracetamol is the safer analgesic in this context.

💡 Pearl 4: Potassium-Containing Salt Substitutes — The Hidden Hyperkalemia Trigger [Practice-based]

Indian patients with hypertension are frequently counselled to “reduce salt.” Many interpret this as “switch to low-sodium salt” and begin using products like Tata Salt Lite, Nutrela Low Sodium Salt, or similar products — which replace 30–50% of NaCl with KCl. This provides a significant occult potassium load. When combined with triamterene’s potassium-sparing effect (and often an ACEi/ARB), this can cause dangerous hyperkalemia. Actively ask every patient on triamterene: “What type of salt do you use at home?” This simple question can prevent a life-threatening event.

💡 Pearl 5: Crystalluria Screening — Practical and Cheap [Practice-based]

Triamterene crystalluria can be detected on a routine urine microscopy — the cheapest and most widely available investigation in India. A urine dipstick alone will NOT detect crystals. Advise every patient on triamterene to have a urine microscopy (not just dipstick) at least every 6–12 months. If triamterene crystals are found (needle-shaped, birefringent under polarised light), increase fluid intake to ≥3 L/day. If crystals persist, switch to amiloride or spironolactone.

💡 Pearl 6: Triamterene in Liddle Syndrome — The One Situation Where It Is the Drug of Choice [Evidence-based]

Triamterene (or amiloride) is the specific, pathophysiology-directed treatment for Liddle syndrome — a rare autosomal dominant cause of early-onset hypertension due to constitutive ENaC activation. Spironolactone is ineffective in Liddle syndrome because the defect is distal to the aldosterone receptor. In any young patient (<30 years) with hypertension, hypokalemia, metabolic alkalosis, low aldosterone, AND low renin who does NOT respond to spironolactone, consider Liddle syndrome and trial triamterene or amiloride. Genetic confirmation (SCNN1B/SCNN1G mutations) is available at select Indian centres. This is a lifelong treatable condition when correctly diagnosed.

VERSION

RxIndia v0.1 — 20 Mar 2026

REFERENCES

The following sources were actually used to generate this monograph entry:

Drug-Specific Monographs / Pharmacology Sources (Tier A)

Goodman & Gilman’s The Pharmacological Basis of Therapeutics, 14th Edition (2023). Chapter: “Diuretics” — Sections on potassium-sparing diuretics, ENaC pharmacology, triamterene pharmacokinetics, pharmacodynamics, adverse effects, and drug interactions. Used extensively for pharmacological depth, PK parameters, mechanism of action, adverse effect profiling, and drug interaction mechanisms.
CDSCO Product Insert — Ditide (Triamterene 50 mg + Benzthiazide 25 mg), GlaxoSmithKline Pharmaceuticals. Used for approved indications in India, FDC composition, and prescribing information as marketed in India. (Note: Limited Indian regulatory documentation available for standalone triamterene monograph — FDC product insert was the primary CDSCO reference.)
National List of Essential Medicines (NLEM) India, 2022 — Ministry of Health and Family Welfare, Government of India. Confirmed that triamterene is NOT listed in the current NLEM. Confirmed NLEM listing status of comparator drugs (spironolactone, hydrochlorothiazide, furosemide, amiloride + HCTZ).
Indian Pharmacopoeia 2022 — Indian Pharmacopoeia Commission, Ghaziabad. Referenced for general monograph standards. Limited specific triamterene monograph detail in IP.
Harrison’s Principles of Internal Medicine, 21st Edition (2022). Chapters on: Hypertension; Disorders of the Kidney; Edematous States; Fluid and Electrolyte Disturbances. Used for clinical context on hypokalemia management, diuretic therapy in heart failure, cirrhotic ascites, and nephrotic syndrome.

Disease Management / Clinical Practice Sources (Tier B)

API Textbook of Medicine, 11th Edition (2019). Association of Physicians of India. Chapters on: Hypertension, Heart Failure, Cirrhosis and Ascites, Nephrotic Syndrome, Diuretic Therapy. Used for Indian clinical practice context, drug selection rationale, and management algorithms.
Indian Guidelines on Hypertension — IV (IGH-IV), 2019. Hypertension India — Cardiological Society of India (CSI) / Association of Physicians of India (API). Used for BP target guidance, step-up antihypertensive algorithm, and positioning of diuretics including potassium-sparing agents.
Cardiological Society of India (CSI) Consensus Statements on heart failure management (most recent). Used for positioning of spironolactone vs triamterene in heart failure context.

Paediatric Sources (Tier C)

IAP Textbook of Pediatrics, 6th Edition (2021). Indian Academy of Pediatrics. Chapters on: Fluid and Electrolyte Management, Paediatric Nephrology, Congenital Heart Disease. Used for general paediatric diuretic use context and electrolyte monitoring recommendations.
IAP Guidelines on Paediatric Nephrology and Cardiology practice — general principles of diuretic dosing in children. Specific triamterene paediatric data derived from expert consensus and Goodman & Gilman (above).

Specific Clinical References

RALES Trial — Pitt B, Zannad F, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med. 1999;341(10):709-717. Referenced for comparison — spironolactone’s mortality benefit in HFrEF, which triamterene lacks.
PATHWAY-2 Trial — Williams B, MacDonald TM, et al. Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial. Lancet. 2015;386(10008):2059-2068. Referenced for comparison — spironolactone’s superiority in resistant hypertension, positioning triamterene as an alternative only when spironolactone is not tolerated.
Ettinger B, Oldroyd NO, Sörgel F. Triamterene nephrolithiasis. JAMA. 1980;244(21):2443-2445. And subsequent case series. Referenced for the signature ADR of triamterene crystalluria and nephrolithiasis.
Beers Criteria — American Geriatrics Society (AGS), 2023 Update. Referenced as additional international guidance on triamterene cautions in elderly patients.
STOPP/START Criteria v2 — O’Mahony D, et al. STOPP/START criteria for potentially inappropriate prescribing in older people: version 2. Age Ageing. 2015;44(2):213-218. Referenced as additional international guidance on diuretic prescribing in elderly.
ICMR AMR Surveillance Data — Indian Council of Medical Research. Not directly applicable to triamterene (non-antimicrobial), but referenced for general Indian clinical context.

Regulatory / Pricing Sources

NPPA (National Pharmaceutical Pricing Authority) — Drug Prices Control Order (DPCO) and NLEM price ceiling notifications. Confirmed that triamterene is NOT under price control.
PMBJP (Pradhan Mantri Bhartiya Janaushadhi Pariyojana) product catalogue — confirmed that triamterene (single-ingredient or FDC) is NOT available through Jan Aushadhi stores.
Online pharmacy platforms (1mg.com, PharmEasy.in) — referenced for current brand availability and approximate retail pricing in India. Prices verified June 2025.

⚖️

Clinical Responsibility

This platform is designed strictly for healthcare professionals. Data provided is synthesized from authoritative pharmacological sources and clinical registries. Do not use for consumer medical decisions. Always verify critical dosing and contraindications with official institutional protocols and peer-reviewed journals.

Content Feedback

Is this information helpful?

Help us improve our clinical database for the medical community.

RxIndia

Loading clinical data...